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A B S T R A C T
Background
Cholera is an acute watery diarrhoea caused by infection with the bacterium Vibrio cholerae, which if severe can cause rapid dehydration
and death. Effective management requires early diagnosis and rehydration using oral rehydration salts or intravenous fluids. In this
review, we evaluate the additional benefits of treating cholera with antimicrobial drugs.
Objectives
To quantify the benefit of antimicrobial treatment for patients with cholera, and determine whether there are differences between classes
of antimicrobials or dosing schedules.
Search methods
We searched the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); PubMed; EMBASE; African Index Medicus; LILACS; Science Citation Index; metaRegister of Controlled Trials; WHO In-
ternational Clinical Trials Registry Platform; conference proceedings; and reference lists to March 2014.
Selection criteria
Randomized and quasi-randomized controlled clinical trials in adults and children with cholera that compared: 1) any antimicrobial
treatment with placebo or no treatment; 2) different antimicrobials head-to-head; or 3) different dosing schedules or different durations
of treatment with the same antimicrobial.
Data collection and analysis
Two reviewers independently applied inclusion and exclusion criteria, and extracted data from included trials. Diarrhoea duration
and stool volume were defined as primary outcomes. We calculated mean difference (MD) or ratio of means (ROM) for continuous
outcomes, with 95% confidence intervals (CI), and pooled data using a random-effects meta-analysis. The quality of evidence was
assessed using the GRADE approach.
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Main results
Thirty-nine trials were included in this review with 4623 participants.
Antimicrobials versus placebo or no treatment
Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment
(MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence). Antimicrobial therapy also
reduced the total stool volume by 50% (ROM 0.5, 95% CI 0.45 to 0.56, 18 trials, 1042 participants, moderate quality evidence) and
reduced the amount of rehydration fluids required by 40% (ROM 0.60, 95% CI 0.53 to 0.68, 11 trials, 1201 participants, moderate
quality evidence). The mean duration of fecal excretion of vibrios was reduced by almost three days (MD 2.74 days, 95% CI -3.07 to -
2.40, 12 trials, 740 participants, moderate quality evidence).
There was substantial heterogeneity in the size of these benefits, probably due to differences in the antibiotic used, the trial methods
(particularly effective randomization), and the timing of outcome assessment. The benefits of antibiotics were seen both in trials
recruiting only patients with severe dehydration and in those recruiting patients with mixed levels of dehydration.
Comparisons of antimicrobials
In head-to-head comparisons, there were no differences detected in diarrhoea duration or stool volume for tetracycline compared to
doxycycline (three trials, 230 participants, very low quality evidence); or tetracycline compared to ciprofloxacin or norfloxacin (three
trials, 259 participants, moderate quality evidence). In indirect comparisons with substantially more trials, tetracycline appeared to have
larger benefits than doxycycline, norfloxacin and trimethoprim-sulfamethoxazole for the primary review outcomes.
Single dose azithromycin shortened the duration of diarrhoea by over a day compared to ciprofloxacin (MD -32.43, 95% CI -62.90
to -1.95, two trials, 375 participants, moderate quality evidence) and by half a day compared to erythromycin (MD -12.05, 95% CI -
22.02 to -2.08, two trials, 179 participants, moderate quality evidence). It was not compared with tetracycline.
Authors’ conclusions
In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects
observed in severely and non-severely ill patients. Azithromycin and tetracycline may have some advantages over other antibiotics.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for treating cholera
Cochrane Collaboration researchers conducted a review of the effects of antibiotics for treating people with cholera. After searching for
relevant trials, they included 39 randomized controlled trials enrolling 4623 people with cholera.
What is cholera and how might antibiotics work
Cholera is a form of severe watery diarrhoea, which spreads from person to person through food and water contaminated with the
bacterium Vibrio cholerae. Cholera is common in places with poor water and sanitation, and sometimes causes large epidemics with
thousands of people falling ill.
Cholera can cause severe dehydration and death, so the main treatment is to give fluids and salt either orally as oral rehydration salts, or
by injection. By clearing the bacteria earlier than the patients own immune system, antibiotics could reduce the duration and severity
of the illness, and reduce onward transmission to other people.
What the research says
Antibiotic treatment shortened the duration of diarrhoea by about one and a half days (the normal duration is between three and four
days), and reduced the total amount of diarrhoea fluid by half. Consequently, the need for rehydration fluids was also reduced by almost
half.
Antibiotic treatment also shortened the period of time where the patient remains contagious by reducing the duration of excretion of
Vibrio cholerae in the diarrhoea.
The benefits of antibiotics were seen in trials recruiting only people with severe dehydration, and in those recruiting people with mixed
levels of dehydration.
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Tetracycline or azithromycin appear more effective than some of the other antibiotics tested, but the choice of which antibiotic to use
will depend on local drug resistance.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antimicrobial drugs versus placebo/no treatment for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Antimicrobial drugs
Comparison: Placebo/no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo/no treatment Antimicrobial drugs
Diarrhoea duration The mean duration of di-
arrhoea in the control
groups ranged from
29.3 to 127.2 hours
The mean duration of di-
arrhoea in the intervention
groups was
36.77 hours shorter
(43.51 to 30.03 hours
shorter)
1013
(19 studies)
⊕⊕⊕©
moderate
1,2,3,4
Stool volume The median volume
across control groups
was 13.5 litres for adults
and 368 ml/kg for chil-
dren
The corresponding vol-
ume with antibiotics
would be 7.3 litres for
adults (6.1 to 7.6 L), and
184 mL/kg for children
(166 to 206 mL/kg)
ROM 0.50 (0.45 to 0.56) 1042
(18 studies)
⊕⊕⊕©
moderate1,2,3,4
Hydration fluid require-
ments
The median volume
across control groups
was 14 litres for adults
and 374 mL/kg for chil-
dren
The corresponding vol-
ume with antibiotics
would be 8.4 litres for
adults (7.4 to 9.5 L), and
224 mL/kg for children
(198 to 254 mL/kg)
ROM 0.60
(0.53 to 0.68)
1201
(11 studies)
⊕⊕⊕©
moderate1,2,3,4
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Duration of pathogen se-
cretion
The mean duration of
pathogen secretion in the
control groups ranged
from
2.97 to 6.0 days
The mean duration of
pathogen secretion in the
intervention groups was
2.74 days shorter
(3.07 to 2.40 days
shorter)
740
(12 studies)
⊕⊕⊕©
moderate5,2,3,4
Deaths - - See comment 299
(7 studies)
- No deaths occurred in
these studies
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: in a sensitivity analysis restricted to the few trials at low risk of selection bias the effect size was
smaller but remained statistically significant.
2 No serious inconsistency: statistical heterogeneity was high, however this related to the size of the effect seen with different antibiotics.
For meta-analysis within individual antibiotics statistical heterogeneity was low.
3 No serious indirectness: although many of the trials are now old, and drug susceptibility patterns have changed, these results are likely
to apply to treatment with antibiotics to which the current V. cholerae isolates are susceptible.
4 No serious imprecision: both limits of the 95% CI represent statistically significant and clinically important effects.
5 Downgraded by 1 for serious risk of bias: only one study was at low risk of selection bias.
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B A C K G R O U N D
Description of the condition
Cholera is an acute watery diarrhoea caused by the Gram-negative
bacteriumVibrio cholera.There are many serogroups ofV. cholerae,
of which O1 and O139 cause disease in humans. V. cholerae lives
in aquatic environments, where it can survive for years in a free
living cycle (Alam 2007). It causes endemic disease in some coun-
tries and regions, but it has the potential to cause epidemics (af-
fecting a large number of individuals within the population) and
pandemics (occurring over a wide geographic area and affecting an
exceptionally high proportion of the population). Children aged
between two and 15 are at highest risk in endemic settings, while
persons of all ages are affected during epidemics (Glass 1982; Sack
2004).
The incidence of cholera has been increasing globally since the be-
ginning of the millennium, with a 24% increase in the number of
cases reported for the years 2004 to 2008 as compared to the years
2000 to 2004 (WHO 2009a). However, the total of 190,130 cases
reported in 2008 is considered to be a gross underestimate, because
many endemic countries do not report cholera and this figure also
excludes the estimated 500,000 to 700,000 cases labelled as acute
watery diarrhoea that occur in some Asian and African countries
(WHO 2009a). Today, the main affected regions worldwide are
in Asia (Bangladesh, India, Thailand, Cambodia, and Vietnam)
and many parts of Africa (including a recent outbreak described
in Zimbabwe) (Chambers 2009; Mintz 2009; Sack 2004; WHO
2009b).More recently, the Haiti outbreak spread cholera to the
neighbouring Dominican Republic, as well as to Cuba andMexico
(Ministry of Public Health and Population 2010; Moore 2014).
V. cholerae is transmitted to humans by the fecal-oral route,
through ingestion of contaminated water or food (Zuckerman
2007). For example, one hypothesis suggests that V. cholerae was
introduced into Haiti by infected Nepalese peacekeeping soldiers
and that the epidemic spread of the organism was due to poor
sanitation (Ceccarelli 2011; Frerichs 2012). The incubation pe-
riod for cholera usually varies between eight to 72 hours, depend-
ing on the infectious dose and gastric acidity (WHO 2001). V.
cholerae O1 and O139 both cause clinical disease by secreting an
enterotoxin with a sub-unit structure comprising five B subunits
and one A subunit (De 1959; Dutta 1959). The B subunits bind
the toxin to a specific receptor (GM1 ganglioside) on the surface
of the intestinal mucosal cells. The A subunit is then released into
the cell where it activates adenylate cyclase, causing a net increase
in cyclic adenosine monophosphate, which blocks the absorption
of sodium by the villous cells. This leads to secretion of chloride by
the crypt cells, followed by secretion of water, resulting in watery
diarrhoea. In endemic settings, about 90% of cholera cases are
defined as mild to moderate and are clinically impossible to dis-
tinguish from other acute watery diarrhoeas such as those caused
by enterotoxigenic Escherichia coli (ETEC) and rotavirus. The re-
maining 10% of cases are labelled as severe cholera.Mortality from
cholera depends on several factors, but is generally preventable.
The overall case fatality reported by the World Health Organi-
zation (WHO) in 2008 was 2.7%, ranging from 0% to 14.3%
in different countries (WHO 2009a). The reported mortality in
Haiti has been as high as 4.6% in some areas, but later decreased
to 1% or less throughout the country (Barzilay 2013).
Successful management of cholera depends on early diagnosis and
prevention of dehydration, or prompt treatment of dehydration
if it develops. Mild to moderate dehydration can be treated with
Oral Rehydration Salts (ORS) solution, but severe dehydration
usually requires intravenous (IV) fluids.
Description of the intervention
The intervention assessed in this review is the impact of antimi-
crobial treatment as an adjunct to rehydration therapy. In the-
ory, antimicrobials will not have an immediate effect, because the
toxin is already bound to intestinal cells. However, they should
affect the duration of the disease by reducing further production
of the toxin, either by inhibiting bacterial protein synthesis (tetra-
cyclines, macrolides) and/or by promoting bacterial cell death.
Shortening the duration of viable pathogen excretion might also
lead to reduced transmission of infection to others and reduced
contamination of the environment.
The WHO recommends antimicrobial therapy only in the man-
agement of severe cases, ie those who need intravenous rehydra-
tion because of severe dehydration; patients who are lethargic or
floppy, unconscious, or unable to drink ORS; or are children with
an absence of tears and very slow return of skin pinch (WHO
2004). The current recommended treatment for adults is a sin-
gle oral dose of doxycyline 300 mg or tetracycline 12.5 mg/kg
six hourly for three days (WHO; Seas 1996). In children under
eight years of age, co-trimoxazole, erythromycin or azithromycin
are recommended (WHO).
The choice of antimicrobial agent is complicated by emerging re-
sistance to antibiotics. Resistance to tetracycline emerged in 1979,
followed by resistance to other antibiotic classes (Mhalu 1979). A
’creeping’ increase in minimal inhibitory concentrations (MICs)
to quinolones has been noted since the 1980s, mediated by chro-
mosomal mutations. Tetracycline resistance, on the other hand, is
plasmid mediated and thus MICs to tetracycline do not increase
gradually. In endemic countries, most strains of V. cholerae are
currently resistant to co-trimoxazole, with variable resistance to
tetracyclines, macrolides and quinolones (Harris 2012). Thus, se-
lection of antibiotic treatment should be directed by the results of
antibiotic susceptibility testing of V. cholerae isolates at the onset
of an outbreak.
Why it is important to do this review
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Cholera epidemics continue to cause significant morbidity and
mortality in many developing countries around the world. In Oc-
tober 2010, an epidemic of cholera started in Haiti and later
spread to the neighbouring Dominican Republic. By October
2012, 604,635 cases and 7436 fatalities had been reported by the
Haitian National Cholera Surveillance System (Barzilay 2013).
Many randomized, controlled clinical trials have been conducted
to evaluate the efficacy of various antimicrobial agents for treat-
ing cholera. Based on the results of these trials, there is a general
consensus that antimicrobial treatment shortens the duration of
diarrhoea and reduces stool volume (Sack 2004; Seas 1996). How-
ever, no systematic review has previously summarized the evidence
to quantify the benefit of antimicrobial treatment with regard to
these outcomes.
With the latest epidemic of cholera in Haiti in mind, we believe
that there is place for a systematic review that would help answer
the following questions: to what extent do antimicrobials shorten
the course of the clinical disease, reduce stool volume and the need
for IV or oral hydration; whether certain antimicrobials or classes
of antimicrobial are more effective than others at treating cholera;
and what is the optimal treatment schedule.
O B J E C T I V E S
• To quantify the benefit of antimicrobial treatment for
patients with cholera.
• To determine whether different antimicrobials have
different effects.
• To determine whether different lengths of treatment or
dosing of antimicrobials have different effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled clinical trials or quasi-randomized studies
(using alternation, date of birth, patient identification number,
weekday).
Types of participants
Patients with diarrhoea caused by V. cholerae O1 or O139, regard-
less of their age and location of management (ie in-hospital or
ambulatory). We included trials that recruited participants with
undiagnosed diarrhoea (eg watery diarrhoea) when they presented
a separate analysis of those patients with proven cholera. In this
case, we only extracted data for proven cholera cases.
Types of interventions
• Any antimicrobial treatment versus placebo/no treatment.
• Any antimicrobial versus a different antimicrobial.
• Different dosing or durations of the same antimicrobials.
We excluded antibiotics that are not in current clinical use, such
as streptomycin, paromomycin, formosulphathiazole, formosul-
phacetamide, and sulfaguanidine.
In our analyses, we did not include treatment arms in which over
90% of the V. cholerae isolates were resistant to the tested antimi-
crobial.
Types of outcome measures
Primary outcomes
• Duration of diarrhoea: from the time of initiation of the
study drug until the end of diarrhoea as defined in the study.
• Stool volume: from the time of initiation of the study drug
until end of diarrhoea as defined in the study.
Secondary outcomes
• All-cause deaths (’deaths’ thereafter) during the acute
disease stage (ie before resolution of diarrhoea).
• Duration of fecal excretion of the pathogen.
• Clinical failure: defined as persistence of watery stools
beyond 48 hours of initiation of the study drug. When this
outcome was reported at various time points, we chose the last
time point reported.
• Bacteriological failure: defined as isolation of V. cholerae
from stools beyond 48 hours of initiation of the study drug.
When this outcome was reported at various time points, we
chose the last time point reported.
• Hydration requirements: defined as the total volume of IV
fluid administered. If not reported, we used data on the total
volume of rehydration fluid administered, and when that was
not reported, we used the total volume of ORS administered.
All outcome definitions, including the time points defining the
outcome (such as schedule and frequency of monitoring), were
recorded.
We intended to assess unscheduled use of IV rehydration, body
weight change, development of severe hypokalaemia, severe hy-
ponatraemia and resistance development, but these outcomeswere
not reported in most trials.
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Search methods for identification of studies
A comprehensive search was conducted with the purpose of iden-
tifying all eligible trials regardless of language, year of publica-
tion, or status of publication (published in peer review journal,
conference proceeding, thesis, or unpublished). The last search of
all databases was conducted in November 2011 and the PubMed
search was updated regularly until March 2014.
Electronic searches
We used the search strategy explained in Table 1. The search pur-
posefully did not include terms related to the intervention because
including the term ’antimicrobial’ would prevent the identifica-
tion of trials that provided only the name of the antimicrobial
without using ’antimicrobial’ as an Index or MeSH term. Listing
all antimicrobial names was not possible since we were not aware
of all types of antimicrobials that could have been assessed. In
PubMed and EMBASE, search terms were used in combination
with the search strategy for retrieving randomized controlled trials
developed by The Cochrane Collaboration (Lefebvre 2011).
We searched the following databases for eligible trials: Cochrane
Infectious Disease Group Specialized Register (CIDG SR); the
Cochrane Central Register of Controlled Trials (CENTRAL),
published in The Cochrane Library; PubMed; EMBASE; African
Index Medicus; LILACS; and the Science Citation Index (CSI).
We searched the following databases for unpublished or ongo-
ing trials: metaRegister of Controlled Trials (mRCT) and the
WHO International Clinical Trials Registry Platform (http://
www.who.int/ictrp/en/) for ongoing or unpublished trials.
Searching other resources
We attempted to contact key persons in agencies and organiza-
tions funding and conducting trials on the treatment of cholera
via email, using our list of identified trials, and asked if they were
aware of other unidentified trials. These persons and agencies in-
cluded: Head of the Epidemic Control Preparedness Programme
(ECPP) at the International Centre for Diarrhoeal Disease Re-
search, Bangladesh (ICDDR,B);Director of theNational Institute
of Cholera and Enteric Diseases (NICED), Kolkata, India; the All
India Institute of Medical Sciences (AIIMS), Delhi, India; the US
Naval Medical Research Unit (NAMRU), Jakarta, Indonesia; the
Naval Medical Research Unit 3 (NAMRU-3), Cairo, Egypt; Epi-
centre, Paris, France; and the Institute Pasteur, Paris, France, and
its network. We also attempted to contact people at the WHO.
References of all included trials were scanned.
We searched the proceedings of the following conferences: the In-
terscience Conference on Antimicrobial Agents and Chemother-
apy (ICAAC); the European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID); and the Infectious Diseases
Society of America (IDSA).
Data collection and analysis
Selection of studies
Two reviewers independently applied inclusion and exclusion cri-
teria, and the search results were documented in an Excel spread-
sheet. Disagreements were resolved by discussion; if they could
not be resolved, we attempted to contact the authors of the trial
to clarify questions on its eligibility. The trials’ reports were scru-
tinized to ensure that multiple publications from the same trial
were included only once. We recorded details of potentially rele-
vant references that were excluded, along with the reason for their
exclusion.
Data extraction and management
A data extraction form in Excel was developed, piloted and fi-
nalized. Two reviewers independently extracted the data from in-
cluded trials into the form. Any disagreements on extracted data
were resolved by discussion. If no consensus could be reached, the
trial authors were contacted to clarify the issue. In the event of
missing or incomplete data, we attempted to contact one or more
of the trial’s authors for clarification.
We extracted descriptive data on the trials, the patients and infec-
tion characteristics, including the V. cholerae serogroup and bio-
type, and resistance rates of theV. cholerae sp. isolates to the antimi-
crobials tested. For dichotomous data, we extracted the number of
patients with event and the number of patients assessed. For con-
tinuous outcomes, we preferentially extracted means and standard
deviations. If reported differently, we converted medians to means
and calculated the variance according to the methods described by
Hozo 2005. Standard errors and other dispersion measures were
converted to standard deviations where possible (Higgins 2008). If
not reported numerically, outcomes were extracted from graphs or
figures presented in the publications (by counting pixels). Studies
are named by first author (abbreviated), year of publication and
trial location using the abbreviations listed in Table 2.
Assessment of risk of bias in included studies
Two reviewers independently assessed potential biases in included
studies and extracted the data into the electronic table. We used a
domain-based evaluation as recommended by theCochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2008). Re-
viewers were not blinded to trial authors, the publication status
or other study characteristics. Each domain was assigned a low or
high risk of bias, using the definitions provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2008).
When there was insufficient information about the process, the
domain was assigned an unclear risk of bias. The following do-
mains were assessed for this review.
• Sequence generation
• Allocation concealment
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• Blinding of participants, personnel and outcome
assessors: we judged a priori that blinding will not affect the
bacteriological outcomes or deaths, and thus did not attempt to
explain results by this item.
• Incomplete outcome data: we assessed the number of
exclusions and attrition for the primary outcomes. We classified
studies as low risk of bias when all randomized patients were
evaluated for a given outcome or up to 10% were missing
without an explanation (Higgins 2008); we classified studies as
unclear risk of bias when the number of randomized patients was
unknown; all other studies were classified as high risk unless the
reasons for attrition were provided and valid.
• Selective outcome reporting: we assessed this domain by
comparing protocol-defined outcomes with those reported.
When the protocol was unavailable, we compared outcome
definitions in the methods with those reported in the results.
When the study reported on the outcomes specified, it was
classified as low risk; if outcomes were not defined in the
protocol/methods or reported outcomes were not specified in the
protocol/methods, the study was classified as high-risk; and
when the outcome was poorly defined in the protocol/methods
(e.g. no time point), we classified the study as unclear risk. We
created a matrix of studies and outcomes (Higgins 2008).
• Other biases: early stop of the trial or one or more of its
arms.
Disagreements regarding extracted data were resolved through dis-
cussion. If no consensus could be reached, we contacted the trial
authors to clarify the issues. In the event of missing or incomplete
data, we contacted one of the trial’s authors and asked for themiss-
ing data.
Measures of treatment effect
For dichotomous data, we compared study groups using risk ra-
tios (RRs). For continuous outcomes, we calculated absolute mean
differences (MDs) when the units of analysis were uniform. For
outcomes dependent on weight that were described in litres or
mL/kg (for example, stool volume, hydration requirements), we
computed the ratio of arithmetic means (ROM, Friedrich 2011;
Friedrich 2012). All effect measures are reported with 95% confi-
dence intervals (CIs).
Unit of analysis issues
When the same trial was included in a single meta-analysis more
than once (because it had multiple intervention groups), we di-
vided the number of events and participants in the placebo arm
for dichotomous outcomes and we divided the number of partic-
ipants for continuous outcomes (Higgins 2008).
Dealing with missing data
We tried to complement all missing data by correspondence with
trial authors (via email). In case of missing data, we performed a
complete case analysis for all outcomes and recorded the number
of dropouts.
Assessment of heterogeneity
We visually inspected the forest plots before performing statistical
tests. Heterogeneity in each meta-analysis was assessed using a Chi
2 test of heterogeneity, with a P value < 0.10 used to indicate
statistical significance, and using the I2 test of inconsistency, with a
value > 50% indicating substantial inconsistency. The importance
of the observed I2 value was interpreted in terms of the magnitude
and direction of the effects.
Assessment of reporting biases
In analyses that included more than 10 trials, we planned to
construct funnel plots of effect estimates against study precision.
Asymmetry was inspected visually to determine publication bias
or other small study effects.
Data synthesis
We created an antimicrobial treatment network based on antimi-
crobial class, as previously described (Ioannidis 2009).We visually
inspected the treatment network to identify missing comparisons.
The following comparisons were conducted:
1. any antimicrobial versus placebo/no treatment,
subcategorized by the antimicrobial;
2. direct comparisons between different antimicrobials or
antimicrobial classes;
3. indirect comparisons between antimicrobials;
4. short versus longer duration of treatment with the same
antimicrobial class, considering the effective antimicrobial
treatment duration (related the duration of administration and
the antibiotic’s half-life);
5. low versus high doses of the same antimicrobial.
We pooled results without significant heterogeneity using the
Mantel-Haenzel fixed-effect model. When significant heterogene-
ity was present and it was still appropriate to pool results, we
used a random-effects model. For dichotomous outcomes with
zero events reported in both arms of a trial, we conducted a meta-
analysis of risk differences. ROMs were pooled using the inverse
variance method on a log scale.
Indirect comparisonswere performed using themethods described
by Bucher 1997 and existing recommendations for reporting of in-
direct comparisons (Donegan 2010). Briefly, for continuous out-
comes the mean difference for A versus B equalled : mean dif-
ference A versus placebo - mean difference B versus placebo; and
variance C versus B equalled: variance A versus placebo + variance
B versus placebo. For dichotomous outcomes, log (risk ratio of A
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versus B) equalled: log(risk ratio of P (control) versus B (treat-
ment)) - log(risk ratio of P (control) versus A (treatment)); and
SE (log risk ratio A versus B) equalled: square root (standard error
of the log risk ratio of P versus B + standard error of the log risk
ratio of P versus A).
Analyses were performed using Review Manager 5 (Review
Manager 5.0). Two authors working independently checked data
entered into Review Manager 5.
Subgroup analysis and investigation of heterogeneity
We primarily investigated heterogeneity by sub-grouping all anal-
yses by the type of antibiotic used. We then also examined the
following subgroups.
• Age of participants: children or adults.
• V. cholerae serogroup: O1 versus O139. (If serogroup was
not reported, we assumed that all V. cholerae strains in studies
conducted before 1992 belonged to the O1 serogroup. Studies in
which over 75% of all isolates were O1 were also included in the
O1 subgroup.)
• Dehydration severity at baseline: trials recruiting only
participants with severe dehydration vs those with variable
inclusion (for clinical outcomes only).
• Timing of stool volume examination: separating studies in
which continuous outcomes were monitored in exact time
intervals of six or eight hours versus those with a vague time
definition.
Sensitivity analysis
• We assessed the effect of allocation concealment on
outcomes.
• We restricted the analysis to trials reporting means and
standard deviations, excluding means that were estimated from
medians.
Assessment of the quality of evidence
We assessed the quality of evidence across each outcome measure
using the GRADE approach. The quality rating across trials has
four levels: high, moderate, low, or very low. RCTs are initially cat-
egorized as high quality but can be downgraded after assessment
of five criteria: risk of bias, consistency, directness, imprecision,
and publication bias (Guyatt 2008). As part of the assessment of
precision we performed sample size calculations for each outcome
to determine if the trials or themeta-analysis were adequately pow-
ered to confidently detect or exclude clinically important effects
(see Table 3; Table 4).
R E S U L T S
Description of studies
Results of the search
Our search yielded a large number of references: 65 were deemed
relevant and the full text of 64 could be retrieved. Twenty-
three studies were excluded for reasons specified in Characteristics
of excluded studies. We were unable to obtain one article
(Chatchai 1994) and three ongoing studies were identified (see
the Characteristics of ongoing studies table).
Included studies
Thirty-nine different trials are included in this review, described
in 41 publications. The trials were conducted between 1964 and
2007, and published between 1964 and 2010. The trials were
predominantly conducted in Bangladesh, India and Pakistan (15,
10, and three trials, respectively), with additional trials inThailand
(2), Sri Lanka (1), Somalia (1), Nigeria (1), Ivory Coast (1), Peru
(2), Turkey (1), Iran (1), and one multi-centre trial (Thailand,
Indonesia, Ivory Coast, Mexico, Israel, and Italy).
Twelve trialswere conducted during an epidemic of cholera and the
remaining were conducted in endemic settings. Most trials were
multi-armed: 16 trials included four ormore study arms, rendering
a large number of different comparisons. We created a treatment
network showing the various comparisons and the number of trials
examining each comparison (Figure 1). All the antimicrobials in
Figure 1, except for azithromycin, were compared to placebo/no
treatment (comparisons not shown in Figure 1).
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Figure 1. An antimicrobial treatment network based on antimicrobial drug or class. This figure describes
the different comparisons in all included studies which compared one antimicrobial vs another antimicrobial
(comparisons vs. placebo/ no treatment not included).
Participant characteristics
A total of 4623 patients took part in the trials, with a median of 77
participants per trial (range 20 to 450). Nine of the trials included
only children, 23 included only adults and the remaining seven
included both. Seventeen trials excluded girls/ women, because of
the difficulty separating stool from urine without a catheter, and
seven further trials did not report on the sex of the study partici-
pants. The case definition in most trials specified a history of acute
watery diarrhoea, lasting 24 hours or less. However, all trials in-
cluded in their final analysis only patients with bacteriologically-
proven cholera. Twenty-seven trials (70%) included somemeasure
of severity in their case definition (eg low blood pressure, severe
dehydration) and six trials excluded patients with severe cholera.
Twenty-eight studies reported exclusion of patients who had re-
ceived antimicrobial therapy prior to enrolment, two trials allowed
inclusion of such patients, and the remaining did not refer to pre-
vious antimicrobial treatment.
Infection characteristics
The isolated V. cholerae strains belonged to serogroup O1 in 23
studies, serogroup O139 in three studies, and both serogroups
in six studies, while the V. cholerae serogroup was not reported
in the remaining studies. We assumed that the strains in studies
conducted before 1992 (four studies) belonged to serogroup O1,
as this was the year in which serogroup O139 first emerged [
ICDDR,b 1993]. Identification of V. cholerae was made by culture
in 12 studies (the earliest conducted in 1963 and the latest in 1996)
and by dark field microscopy in 15 (the earliest published in 1971
and the latest conducted in 2002); the remaining publications did
not describe the methods of laboratory confirmation.
Nineteen studies reported that all isolates were susceptible to the
study drugs, while 13 studies did not report susceptibility data.
The remaining seven studies reported various degrees of resistance
to several different antimicrobials:
• Tetracycline resistance: Grados 1996 PER (7%); Khan
1995b BGD (100%); Rabbani 1989 BGD (13.3%); Roy 1998
BGD (24%)
• Cotrimoxazole: Kabir 1996 BGD (23%)
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• Erythromycin: Bhattacharya 1990 IND (100%); Kabir
1996 BGD (23%)
• Furazolidone: Rabbani 1989 BGD (22.2%); Rabbani 1991
BGD (10%).
We excluded study arms with 100% resistance from the meta-
analysis.
Excluded studies
Most excluded studies were non-randomized (see Characteristics
of excluded studies). Two studies conducted by the same group
were declared randomized, but the randomization methods were
not described and differences between groups at baseline suggested
a lack of adequate randomization ( Mazumder 1974; Mazumdar
1977). We could not establish contact with the authors and these
trials were excluded. We excluded a four-armed pseudo-random-
ized trial (using alternation) conducted in 1950, which assessed
sulphaguanidine, formosulphathiazole, and formosulphacetamide
against no treatment (Lahiri 1951). These antimicrobials are no
longer used in humans and the mortality in this trial was higher
in the antimicrobial arms (30 to 34%) than in the no treatment
arm (18%). Finally, we excluded a trial conducted in 1964 in
the Philippines (Uylangco 1965), which was a pseudo-random-
ized trial (using alternation) comparing sulphaguanidine versus no
treatment.
Risk of bias in included studies
A visual summary of the risk of bias assessment can be seen in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Nineteen studies described an adequate method for generating a
random allocation sequence. Five studies used alternate allocation
based on the order of arrival at hospital and were considered to
be at high risk of selection bias (Carpenter 1964 IND; Karchmer
1970 PAK; Lindenbaum 1967a PAK; Lindenbaum 1967b PAK;
Rahaman 1976 BGD). The remaining trials did not describe their
methods of randomization and so are at unclear risk.
Fourteen studies described an adequate method for concealing
allocation and were judged to be at low risk of bias, and 20 studies
did not describe allocation concealment and so are at unclear risk
of bias.
Blinding
Sixteen trials were double blinded, while in two trials the outcome
assessor alone was blinded. The remaining 21 trials were open-
labelled.
Incomplete outcome data
We examined incomplete outcome data reporting for the two pri-
mary outcomes. Out of 30 trials reporting on diarrhoea duration,
nine were classified as low risk, 11 as high risk and the remainder
were classified as unclear risk of incomplete outcome because the
number of randomized patients was not explicitly stated. Out of
29 trials reporting on stool volume, 13 were low risk, eight were
high risk and the remainder were unclear.
Selective reporting
Study protocols were not available. The primary outcome was not
defined in the methods section in eight (20.5%) of the publica-
tions. In most publications (26 out of 39, 66.7%), the primary
outcomes were defined without specifying the time point for as-
sessment, while the primary outcomes were fully defined in five
publications. When primary outcomes were defined, 13 studies
defined a single primary outcome, six studies defined more than
one outcome and 12 studies included all outcomes as ’primary’.
Primary and secondary outcomes defined in the methods were re-
ported in the results quantitatively in all publications. The out-
come matrix showed that out of the 39 included studies, the num-
ber of studies reporting review-defined outcomes were as follows:
• diarrhoea duration: 29
• volume of diarrhoea: 29
• deaths: 14
• duration of pathogen excretion: 16
• microbiological failure: 31
• clinical failure: 18
• volume of rehydration fluids (IV or orally): 24.
Other potential sources of bias
Eight trials were sponsored by a pharmaceutical company that
manufactured one of the study drugs; another six received only
the study drug from the company. Fourteen studies were under
academic sponsorship, and the remaining 11 publications did not
specify whether the trial was sponsored or not. Approval of an
ethics committee was reported in 10 trials (24%) and informed
consent was reported in 22 trials (54%).
Effects of interventions
See: Summary of findings for the main comparison
Antimicrobial drugs versus placebo/no treatment for treating
cholera; Summary of findings 2 Azithromycin versus
ciprofloxacin for treating cholera; Summary of findings 3
Azithromycin versus erythromycin for treating cholera; Summary
of findings 4 Tetracycline versus doxycycline for treating cholera;
Summary of findings 5 Tetracycline versus quinolones for
treating cholera; Summary of findings 6 Doxycycline versus
quinolones for treating cholera; Summary of findings 7 Short
compared to long duration of antimicrobials for treating cholera
Section 1. Antimicrobials versus placebo/ no
treatment
A total of 23 trials included a comparison of antimicrobials versus
placebo/no treatment, contributing to one or more of the out-
comes detailed below. The last trial was completed in 1994.
Primary analysis
Diarrhoea duration
On average, antimicrobials reduced the duration of diarrhoea by
about one and a half days compared to placebo or no treatment
(MD -36.77 hours, 95% CI -43.51 to -30.03, 18 trials, 1479
participants, Analysis 1.1). However, there were statistically sig-
nificant subgroup differences in the magnitude of the effect (P
< 0.00001). Tetracycline, the most studied antibiotic, shortened
the duration of diarrhoea by almost two days (MD -47.38 hours,
95% CI -52.36 to -42.41, I2 = 0%, 11 trials, 665 participants);
doxycycline shortened the duration by just over one day (MD -
25.44 hours, 95% CI -38.90 to -11.99, I2 = 50%, three trials, 91
participants); and norfloxacin shortened the duration by less than
half a day (MD -10.80 hours, 95% CI -14.13 to -7.48, I² = 0%,
three trials, 123 participants).
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Stool volume
Thirteen trials reported stool volume as total litres excreted, while
four studies reported it as mL/kg body weight. The results were
highly skewed in most trials.
Overall, the mean stool volume was 50% lower in those treated
with antibiotics compared to placebo/no treatment (ROM 0.50,
95% CI 0.45 to 0.56, 17 trials, 1716 participants, Analysis 1.2).
As with diarrhoea duration, there were statistically significant sub-
group differences between antibiotics (P = 0.01). Tetracycline was
again the most studied antibiotic and reduced stool volume by
56% (ROM 0.44, 95% CI 0.39 to 0.50, I2 =0%, 12 trials, 771
participants). Large effects were also seen with norfloxacin (two
trials), ciprofloxacin (one trial), doxycycline (three trials), chlo-
ramphenicol (three trials), furazolidone (five trials), and ampicillin
(one trial).
Deaths
No deaths were reported in all trials, although only six trials ex-
plicitly stated that no deaths occurred (Analysis 1.3).
Clinical failure
Clinical failure was variably assessed between 48 to 96 hours after
enrolment to the study or from starting to take the study drugs.
Overall, clinical failure was significantly lower with antimicrobial
treatment (RR 0.21, 95% CI 0.13 to 0.34, 10 trials, 1023 pa-
tients, Analysis 1.4). Tetracycline reduced the risk of clinical fail-
ure by 90% (RR 0.10, 95% CI 0.05 to 0.22, I2 = 46%, six tri-
als, 431 participants), and statistically significant effects were also
seen with fleroxacin (one trial), trimethoprim-sulfamethoxazole
(TMP-SMX; two trials), chloramphenicol (two trials), and sul-
fometoxine (one trial).
Hydration requirements
Eight trials reported total hydration fluid requirement as litres,
while three trials reported it as mL/kg body weight.
Overall, the total volume of hydration fluid required was 40%
lower in patients given antibiotics (ROM 0.60, 95% CI 0.53 to
0.68, 11 trials, 1201 participants, Analysis 1.5). The effect was
slightly greater than the pooled total with tetracycline (ROM0.50,
95% CI 0.43 to 0.58, I2 =19%, eight trials, 604 participants),
and lower for doxycycline (ROM 0.76, 95% CI 0.57 to 1.02, I2
= 37%, two trials, 66 participants) and norfloxacin (ROM 0.72,
95% CI 0.60 to 0.86, I2 = 57%, two trials, 98 participants ).
Beneficial effects were also seen with chloramphenicol (two trials)
and amoxicillin (one trial).
Pathogen excretion duration
Themean duration of pathogen excretion was significantly shorter
in patients given antibiotics (MD -2.74 days, 95% CI -3.07 to -
2.40, 11 trials, 1009 participants, Analysis 1.6). Tetracycline was
the most studied antibiotic and reduced the duration of excretion
by three days (MD -3.05 days, 95% CI -3.43 to -2.67, I2 = 60%,
11 trials, 616 participants). Large beneficial effects were also seen
with TMP-SMX (one trial), chloramphenicol (two trials), and fu-
razolamide (three trials). All studies monitored stools for pathogen
excretion daily.
Bacteriological failure
As for clinical failure, microbiological failure was variably assessed
at 48 to 96 hours after enrolment to study or from start of the
study drugs.
Overall, bacteriological failure was significantly lower with antimi-
crobial therapy (RR 0.25, 95%CI 0.16 to 0.39, 15 trials, 1147 pa-
tients, Analysis 1.7), but with significant subgroup differences (P
< 0.00001) and significant heterogeneity within some subgroups.
Considerable heterogeneity was present in the analysis of tetracy-
cline, but all studies pointed in the same direction (RR 0.28, 95%
CI 0.13 to 0.64, I2 = 86%, seven trials, 320 participants), with
large reductions seen in small trials of doxycycline (two trials),
norfloxacin (three trials), fleroxacin (one trial), ciprofloxacin (one
trial), and erythromycin (three trials).
Sensitivity analysis
Risk of bias
We evaluated the possible influence of poor study design on the
observed effects of antimicrobial treatment by conducting a sensi-
tivity analysis against the risk of selection bias. For duration of di-
arrhoea (Analysis 2.1), stool volume (Analysis 2.2), hydration re-
quirements (Analysis 2.4), clinical failure (Analysis 2.3), and bac-
teriological failure (Analysis 2.6), the largest effects were observed
in trials at high risk of selection bias and the smallest effects in trials
at low risk of bias. Nevertheless, when the analysis was restricted
to those to studies at low risk of bias, the benefits of antibiotics
remained both statistically and clinically significant.
Conversion of medians to means
When excluding trials reporting results in medians (which we con-
verted into means), the results remained almost identical to the
main analysis (data not shown).
Time definition
For stool volume, the time interval for stool output assessment
was eight hours in 16 studies, six hours in six studies, 24 hours or
more in four studies, and not reported in 13 studies.Heterogeneity
dropped significantly in the groupof trialswith exact time intervals
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of eight hours (MD -42.21 hours, 95% CI -47.64 to -36.78, I² =
45%, nine trials, 1038 patients, Analysis 3.1).
For clinical and bacteriological failure, there were no significant
differences in effects between trials assessing failure at 48, 72 or
96 hours (Analysis 3.2; Analysis 3.3).
Subgroup analysis
Age of participants
No statistically significant subgroup differences were seen (data
not shown).
Cholera serogroups
No statistically significant subgroup differences were seen (data
not shown).
Level of dehydration at baseline
The effect of antimicrobials was smaller in trials where all patients
were severely dehydrated at baseline compared to studies with
broader inclusion criteria (range 0 to 88% severely dehydrated)
for duration of diarrhoea (test for subgroup differences P = 0.005,
Analysis 4.1), stool volume (P = 0.07, Analysis 4.2), and hydration
requirements (P = 0.04, Analysis 4.4). There were no subgroup
differences for clinical failure (P = 0.77, Analysis 4.3).
Antimicrobial resistance
Restriction of the analysis of bacteriological failure to studies re-
porting that all cholera isolates were susceptible to the adminis-
tered antimicrobials resulted in similar results to the overall anal-
ysis (RR of 0.13, 95% CI 0.06 to 0.27, Analysis 5.1).
Small study effects
The funnel plots for most outcomes in the comparison of antimi-
crobial versus placebo/no treatment did not show a small study
effect; only in the clinical and microbiological failure analyses did
small studies tend to show a larger effect, but these analyses in-
cluded only a small proportion of existing studies.
Assessment of quality of evidence
This comparison is summarized in Summary of findings for the
main comparison. The evidence for the large effect of antibiotics
on the duration of diarrhoea, total stool volume, fluid require-
ment, and pathogen excretion duration was judged to be of mod-
erate quality, meaning we have reasonable confidence in these re-
sults. We downgraded the quality of evidence from high to mod-
erate because the effects appear to be exaggerated in trials at high
risk of selection bias. We did not downgrade for inconsistency, as
much of the observed heterogeneity was explained by differences
between antibiotic classes and differences in the timing of out-
come measurements. We also did not downgrade for indirectness
despite many of the trials being old. We consider the observed
effects applicable to effective antibiotics today.
Section 2. Comparison between different
antimicrobials
Direct comparisons are addressed, followed by indirect compar-
isons where relevant. Funnel plots were not drawn for all head-to-
head comparisons because of the paucity of trials in most compar-
isons.
Azithromycin versus ciprofloxacin
Two trials have directly compared single doses of azithromycin
(effective duration of four days) and ciprofloxacin (effective dura-
tion of 12 hours) among children (Kaushik 2010 IND) and adults
(Saha 2006 BGD).
Compared to ciprofloxacin, treatment with azithromycin reduced
the mean duration of diarrhoea by over a day (MD -32.43 hours,
95%CI -62.90 to -1.95, two trials, 375 participants, Analysis 6.1),
reduced stool volume by about two-thirds (ROM 0.35, 95% CI
0.28 to 0.44, one trial, 195 participants, Analysis 6.2), reduced
hydration requirements by about a third (ROM0.66, 95%CI 0.52
to 0.83, two trials, 375 participants, Analysis 6.3), and reduced
bacteriological failure at 48 to 72 hours by over three-quarters (RR
0.23, 95% CI 0.16 to 0.34, two trials, 375 participants, Analysis
6.5).
This comparison is summarized in Summary of findings 2. The
quality of the evidence for a reduction in diarrhoea duration was
judged to be moderate. We downgraded the evidence because the
trial that demonstrated the largest effect had baseline imbalances
favouring azithromycin (Saha 2006 BGD). The effects on stool
volume and bacteriological failure were further downgraded to
low quality due to concerns about indirectness and inconsistency,
respectively.
Azithromycin versus erythromycin
One trial directly compared single dose azithromycin (effective
duration of four days) with three days of erythromycin (Khan
2002 BGD), and one trial compared a three-day regimen of both
drugs (Bhattacharya 2003 IND).
Compared to erythromycin, azithromycin reduced the duration
of diarrhoea by half a day (MD 12.05 hours, 95% CI -22.02 to -
2.08, two trials, 179 participants, Analysis 7.1), and reduced the
total stool volume by a third (ROM 0.69, 95% CI 0.56 to 0.85,
two trials, 172 participants, Analysis 7.2).Hydration requirements
were lower with azithromycin, but this did not reach statistical
significance (two trials, 172 participants, Analysis 7.3), and no
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differences were observed for clinical failure (Analysis 7.4) or bac-
teriological failure (Analysis 7.5).
This comparison is summarized in Summary of findings 3. The
quality of evidence for the reduction in diarrhoea duration and
stool volume was judged to be of moderate quality.
Tetracycline versus doxycycline
Three trials directly compared tetracycline with doxycycline. In
two trials tetracycline was given four times daily for four days (De
1976 IND; Rahaman 1976 BGD), and in one trial tetracycline
was given four times daily for two days (Alam 1990 BGD). All
trials administered a total dose of 300 mg of doxycycline, spread
over three days (Rahaman 1976 BGD), two days (De 1976 IND)
or given as a single dose (Alam 1990 BGD).
Overall, no consistent clinically important differences were ob-
served for diarrhoea duration, stool volume, or hydration re-
quirements (three trials, 230 participants, Analysis 8.1; Analysis
8.2,Analysis 8.4), or for duration of pathogen excretion (two tri-
als, 66 participants, Analysis 8.5). Only a few patients with bacte-
riological failure were reported, but this reached statistical signif-
icance in favour of tetracycline (RR 0.20, 95% CI 0.06 to 0.68,
two trials, 198 participants, Analysis 8.6).
This comparison is summarized in Summary of findings 4. The
evidence of no difference between antimicrobials was downgraded
to low quality due to concerns about the risk of bias of the studies
and their age, with the most recent study being 25 years old.
This direct evidence is in contrast to the indirect evidence com-
paring tetracycline (10 trials) and doxycycline (three trials) with
placebo/no treatment. In this analysis, diarrhoea duration was al-
most a day shorter in the trials using tetracycline compared with
the trials using doxycycline (MD 21.94 hours, 95% CI -36.29
to -7.59, Analysis 1.1), while the stool volume reduction was sig-
nificantly higher with tetracycline (ROM 0.44, 95% CI 0.39 to
0.50) compared to doxycycline (ROM0.64, 95%CI 0.51 to 0.81,
Analysis 1.2, P = 0.004 for subgroup difference).
Tetracycline versus quinolones
Three trials compared tetracycline with quinolones. The three tri-
als compared tetracycline 500 mg four times daily for three days
with: ciprofloxacin 1 g single dose (Khan 1995a BGD); ciproflo-
xacin 250 mg once daily for three days (Gotuzzo 1995 PER); and
norfloxacin 400 mg twice daily for three days (Moolasarat 1998
THA).
There were no statistically significant differences in the duration
of diarrhoea (three trials, 259 participants, Analysis 9.1), stool
volume (two trials, 234 participants, Analysis 9.2), clinical failure
(one trial, 202 participants, Analysis 9.4), hydration requirements
(two trials, 234 participants, Analysis 9.5), duration of pathogen
excretion (one trial, 25 participants, Analysis 9.6), or bacteriolog-
ical failure (two trials, 234 participants, Analysis 9.7).
This evidence of no difference was judged to be of low tomoderate
quality (see Summary of findings 5).
In indirect comparisons, tetracycline appeared to have a larger ef-
fect on diarrhoea duration than norfloxacin, compared to placebo/
no treatment (P < 0.002 for subgroup difference, Analysis 1.1).
Statsitically significant subgroup differences in favour of tetracy-
cline were also seen for stool volume (P=0.004, Analysis 1.2) and
hydration requirements (P=0.003, Analysis 1.5).
Tetracycline versus TMP-SMX
Three trials compared tetracycline (500 mg four times daily for
three days) versus TMP-SMX (twice daily for three days) (Francis
1971 NGA; Gharagozoloo 1970 IRN; Grados 1996 PER).
Compared to TMP-SMX, diarrhoea duration was slightly shorter
in those treated with tetracycline (MD -6.44 hours, 95% CI -
10.93 to -1.96, two trials, 152 participants, Analysis 10.1); stool
volume was not reported. Clinical failure was also lower with tetra-
cycline (RR 0.56, 95% CI 0.34 to 0.92, two trials, 152 partici-
pants, Analysis 10.2). In one small trial, pathogen excretion was
reduced by a day with tetracycline (MD -1.1 days, 95% CI -1.74
to -0.46, one trial, 45 participants, Analysis 10.3), but there was
no difference in bacteriological failure across all three trials (three
trials, 173 participants, Analysis 10.4).
In indirect comparisons, tetracycline was associated with a greater
reduction in diarrhoea duration (MD -47.38 hours tetracycline vs
-30.76 hours TMP-SMX, test for subgroup differences P=0.09,
Analysis 1.1) and a greater reduction in clinical failure (RR 0.10
tetracycline vs 0.33 TMP-SMX, test for subgroup differences P =
0.02 , Analysis 1.4).
Tetracycline versus other antibiotics
Tetracycline has also been directly compared to: chloramphenicol
(three trials); furazolidone (four trials); ampicillin (two trials); ery-
thromycin (two trials); and sulphadoxine (two trials).
Tetracycline was more effective than chloramphenicol for all out-
comes examined,without statistically significant differences (Anal-
ysis 11.1; Analysis 11.2; Analysis 11.4; Analysis 11.3), except for
pathogen excretion duration where the difference of about one
day was statistically significant (Analysis 11.5).
Tetracycline was also more effective than furazolidone for most
outcomes examined, with these differences statistically significant
for diarrhoea duration (mean difference -16.00 hours, 95% CI -
31.26 to -0.74, Analysis 12.1), stool volume (Analysis 12.2), hy-
dration requirements (Analysis 12.5), and clinical failure (Analysis
12.4). There was no difference in deaths (Analysis 12.3).
For the remaining comparisons (versus ampicillin, erythromycin
and sulphadoxine), diarrhoea duration was not reported. Consis-
tent clinical differences were not detected (data not shown), ex-
cept for an advantage of tetracycline in hydration requirements
in comparison to ampicillin or erythromycin (ROM 0.43, 95%
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CI 0.25 to 0.73, Roy 1998 BGD) and in bacteriological failure
in comparison to sulphadoxine (RR 0.14, 95% CI 0.02 to 0.96,
Mihindukulasurya 1976 LKA).
Doxycycline versus quinolones
Four trials were included overall, with three of the trials having a
similar treatment duration (single dose) (Dutta 1996 IND; Khan
1995a BGD; Khan 1996 BGD) and one trial having a longer
duration (Usubutun 1997 TUR). Ciprofloxacin was examined in
three trials and norfloxacin in one trial (Dutta 1996 IND).
There was no clinically or statistically significant difference in di-
arrhoea duration (Analysis 13.1), stool volume (Analysis 13.2) or
deaths (Analysis 13.3). Hydration requirements were lower with
quinolones, although there was only a small magnitude of effect
based mostly on the results of a single trial (Analysis 13.4). Bacte-
riological failure occurred more frequently with doxycycline (RR
5.84, 95% CI 2.70 to 12.65, Analysis 13.5).
The quality of the evidence was rated low to moderate for the
main outcomes (Summary of findings 6).
For indirect comparisons, no differences between doxycycline and
quinolones were observed.
Erythromycin versus ciprofloxacin
Three trials compared erythromycin with ciprofloxacin (Khan
1995a BGD; Khan 1995b BGD; Saha 2005 BGD) and found no
statistically significant differences (data not shown).
TMP-SMX versus other antibiotics
Two trials compared TMP-SMXwith erythromycin (Burans 1989
SOM; Kabir 1996 BGD) and found no statistically significant
differences (Analysis 14.1; Analysis 14.2; Analysis 14.3).
A single trial compared TMP-SMX with norfloxacin (Lolekha
1988 THA), but reported only diarrhoea duration; it found no
significant difference between the drugs (data not shown).
Section 3. Short versus long duration of treatment
(mean difference < 0 and risk ratio < 1 in favour of
short duration)
Only the few trials (eight) comparing the same antimicrobial or
antimicrobial class were included in this comparison. We divided
the trials into subgroups according to the effective duration of
treatment in the long treatment arm (24, 48, 72, or 96 hours).
The duration of treatment in the short treatment arm was al-
ways shorter than 24 hours. This comparison is summarized in
Summary of findings 7.
For clinical outcomes; one trial found that three days of norfloxacin
(400 mg twice daily) was superior to a single dose (800 mg), but
the remaining trials found no statistically significant benefits with
longer durations; diarrhoea duration (seven trials, Analysis 15.1),
stool volume (eight trials, Analysis 15.2), hydration requirements
(six trials, Analysis 15.3), clinical failure (two trials, Analysis 15.5).
In three trials comparing long and short durations of tetracycline,
doxycycline and furazolidine respectively, there was a consistent
reduction in the duration of pathogen excretion (MD 0.40 days,
95% CI 0.11 to 0.69, three trials, Analysis 15.4). There were
also more bacteriological failures with shorter treatment (RR 1.53,
95% CI 1.01 to 2.32, Analysis 15.6), although the trials were
generally at high risk of bias, and underpowered to detect these
effects so provide only low quality evidence of this effect.
Section 4. Low versus high dose of treatment
The identified comparisons are detailed in Table 5. As antimicro-
bials and schedules were different, the studies could not be com-
bined. No differences were detected in any trials for any compar-
isons, except for a comparison between single-dose doxycycline
200 mg versus 300 mg for adults (and 4 mg/kg versus 6 mg/kg
for children). In this case, an advantage was found with the high
dose for diarrhoea duration (two trials) and pathogen excretion
duration (one trial, data not shown).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Azithromycin versus ciprofloxacin for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Azithromycin (single dose of 1 g or 20 mg/kg)
Comparison: Ciprofloxacin (single dose of 1 g or 20 mg/kg)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Ciprofloxacin Azithromycin
Diarrhoea duration The mean duration of diar-
rhoea in the control groups
ranged from
71.5 to 78 hours
The mean duration of di-
arrhoea in the intervention
groups was
32.43 hours shorter
(62.9 to 1.95 hours shorter)
375
(2 studies)
⊕⊕⊕©
moderate1,2,3,4
Stool volume The median volume across
control groups was 322 mL/
kg
The corresponding volume
with azithromycin would be
113 ml/kg (90 to 142 mL/kg)
ROM 0.35
(0.28 to 0.44)
195
(1 study)
⊕⊕©©
low5,6,7
Bacteriological failure 492 per 1000 113 per 1000
(79 to 167 per 1000)
RR 0.23
(0.16 to 0.34)
375
(2 studies)
⊕⊕©©
low1,8,3,7
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.19
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1 Downgraded by one for serious risk of bias: the study showing the largest effects had baseline imbalances which would favour
azithromycin and was sponsored by a pharmaceutical company. The second trial was open label.
2 No serious inconsistency: statistical heterogeneity was high (I2 = 97%), but both studies found effects in favour of azithromycin and
the heterogeneity was in the size of this effect.
3 No serious indirectness: one study was in children in India, one study was in adults in Bangladesh.
4 No serious imprecision: both studies found effects that were statistically significant and clinically important.
5 Downgraded by one for serious risk of bias: this single study had baseline imbalances which would favour azithromycin and was
sponsored by a pharmaceutical company.
6 Downgraded by one for serious indirectness: only a single trial on adults in India assessed this outcome.
7 No serious imprecision: both limits of the 95% confidence intervals imply clinically important benefits.
8 Downgraded by one for serious inconsistency: a large effect was seen in the trial from India at high risk of bias; in the second trial, very
few episodes of treatment failure were recorded, with both drugs performing well.
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Azithromycin versus erythromycin for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Azithromycin (20 mg/kg single dose, one trial; 10 mg/kg once daily for three days, one trial)
Comparison: Erythromycin (12.5 mg/kg four times daily for three days, both trials)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Erythromycin Azithromycin
Diarrhoea duration The mean duration of diar-
rhoea in the control groups
ranged from
33.5 to 42.0 hours
The mean duration of di-
arrhoea in the intervention
groups was
12.05 hours shorter
(22.02 to 2.08 hours shorter)
179
(2 studies)
⊕⊕⊕©
moderate1,2,3,4
Stool volume The median volume across
control groups was 3.1 litres
in adults or 186 mL/kg in
children
The corresponding volume
with azithromycin would be 2.
1 litres in adults (1.7 to 2.6
litres), or 128 mL/kg in chil-
dren (104 to 158 mL/kg)
ROM 0.69 (0.56 to 0.85) 172
(2 studies)
⊕⊕⊕©
moderate1,3,4,5
Bacteriological failure 126 per 1000 197 per 1000
(101 to 381 per 1000)
RR 1.56
(0.80 to 3.02)
179
(2 studies)
⊕⊕©©
low1,3,6
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Downgraded by one for serious risk of bias: one study had high loss to follow-up >25% in both groups, and one was sponsored by
the drug manufacturer.
2 No serious inconsistency: statistical heterogeneity was high (I2 = 70%), but both studies found effects in favour of azithromycin and
the heterogeneity was only in the size of this effect.
3 No serious indirectness: both studies were in children, with one study from India and one from Bangladesh.
4 No serious imprecision: both trials found statistically significant effects.
5 No serious inconsistency: statistical heterogeneity was low.
6 Downgraded by one for serious imprecision: the 95% CI is wide and includes important differences between drugs.
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Tetracycline versus doxycycline for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Tetracycline (four times daily for two to four days)
Comparison: Doxycycline (300 mg total dose given over one to three days)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Doxycycline Tetracycline
Diarrhoea duration The mean duration of diar-
rhoea in the control groups
ranged from
15 to 32 hours
The mean duration of di-
arrhoea in the intervention
groups was
2.01 hours shorter
(8.21 hours shorter to 4.19
hours longer)
230
(3 studies)
⊕⊕⊕©
moderate1,2,3,4
Stool volume The median volume across
control groups was3 litres
The corresponding volume
with tetracycline would be 2.9
litres (2.5 to 3.4 litres)
ROM 0.97 (0.83 to 1.14) 336
(3 studies)
⊕⊕⊕©
moderate1,2,3,4
Bacteriological failure 153 per 1000 31 per 1000
(9 to 104 per 1000)
RR 0.2
(0.06 to 0.68)
198
(2 studies)
⊕⊕⊕©
moderate5,6
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 No serious risk of bias: one trial was at low risk of selection bias and this study found no effect consistent with the other two trials.
2 Downgraded by one for serious inconsistency: statistical heterogeneity is high (I2 = 66%), with one trial showing a benefit of six hours
and two showing no effect.
3 No serious indirectness: the studies were conducted in children and adults in India and Bangladesh. Of note is that tetracycline was
only given for two days in two of these trials.
4 No serious imprecision: the 95% CI probably excludes clinically important effects.
5 No serious risk of bias: one study was at low risk of selection bias and one was at unclear risk.
6 Downgraded by one for serious imprecision: the number of events is very low and underpowered to have confidence in this result.
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Tetracycline versus quinolones for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Tetracycline (500 mg four times daily for three days)
Comparison: Quinolone (Ciprofloxacin 1 g single dose or 250 mg once daily for three days, or norfloxacin 400 mg twice daily for three days)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Quinolone Tetracycline
Diarrhoea duration The mean duration of diar-
rhoea in the control groups
ranged from 30 to 51 hours
The mean duration of di-
arrhoea in the intervention
groups was 0.91 hours
shorter
(4.53 hours shorter to 2.72
hours longer)
259
(3 studies)
⊕⊕⊕©
moderate1,2,3,4
Stool volume The median volume across
control groups was 215 mL/
kg
The corresponding volume
with tetracycline would be 187
ml/kg (161 to 219 mL/kg)
ROM 0.87 (0.75 to 1.02) 236
(2 studies)
⊕⊕©©
low1,2,5
Bacteriological failure 9 per 1000 9 per 1000
(1 to 59 per 1000)
RR 0.99
(0.14 to 6.82)
234
(2 studies)
⊕⊕©©
low1,2,6
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Downgraded by one for serious risk of bias: only one trial was at low risk of selection bias; this study found no significant effect
consistent with the other two trials.
2 No serious inconsistency: statistical heterogeneity is low (I2 = 0%).
3 No serious indirectness: the studies were conducted in children and adults in Bangladesh, Peru and Thailand. The most recent trial was
conducted in 1996.
4 No serious imprecision: the 95% CI probably excludes clinically important effects.
5 Downgraded by one for serious imprecision: the 95% CI includes both clinically important effects and no difference.
6 Downgraded by one for serious imprecision: the number of events is very low and underpowered to have confidence in this result.
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Doxycycline versus quinolones for treating cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Doxycycline (300 mg single dose or 100 mg twice daily for three days)
Comparison: Quinolones (Ciprofloxacin 1 g single dose or norfloxacin 800 mg single dose or norfloxacin 400 mg BD for three days)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Quinolones Doxycycline
Diarrhoea duration The mean duration of diar-
rhoea in the control groups
ranged from 35 to 60 hours
The mean diarrhoea duration
in the intervention groups was
4.64 hours longer
(2.14 hours shorter to 11.42
hours longer)
126
(3 studies)
⊕⊕©©
low1,2,3,4
Stool volume The median volume across
control groups was 148 mL/
kg
The corresponding volume
with doxycycline would be
149 mL/kg (121 to 185 mL/
kg)
ROM 1.01 (0.82 to 1.25) 435
(4 studies)
⊕⊕©©
low5,3,6
Bacteriological failure 32 per 1000 188 per 1000
(87 to 408 per 1000)
RR 5.84
(2.7 to 12.65)
386
(4 studies)
⊕⊕©©
low5,3,6
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Downgraded by one for serious risk of bias: none of the trials concealed allocation adequately enough to be at low risk of selection bias.
2 No serious inconsistency: statistical heterogeneity is low (I2 = 31%).
3 No serious indirectness: the studies were conducted in children and adults in Bangladesh, Turkey and India. The most recent trial was
conducted in 1994.
4 Downgraded by one for serious imprecision: all three trials are small and the overall 95% CI includes a mean difference of almost half
a day.
5 Downgraded by one for serious risk of bias: only one of the trials concealed allocation adequately enough to be at low risk of selection
bias.
6 Downgraded by one for serious imprecision: the 95% CI includes clinically important benefits and harms.
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Short compared to Long duration of antimicrobials for cholera
Patient or population: Adults and children with cholera diarrhoea
Intervention: Short duration of treatment
Comparison: Long duration of treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Long duration Short duration
Diarrhoea duration - - MD 0.34
(-4.65 to 5.32)
431
(7 studies)
⊕⊕©©
low1,2
Stool Volume - - ROM 1.05
(0.94 to 1.18)
496
(8 studies)
⊕⊕©©
low1,2
Bacteriological failure 93 per 1000 142 per 1000
(94 to 216)
RR 1.53
(1.01 to 2.32)
672
(9 studies)
⊕⊕©©
low1,3
*The basis for the assumed risk (eg the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; ROM: Ratio of means.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by one for serious risk of bias: Only one trial adequately described a method of allocation concealment to prevent the risk
of selection bias.
2 Downgraded by one for serious inconsistency: Statistically significant benefits were seen in one trial comparing Norfloxacin 400 mg
twice daily for three days with 800 mg once only. Other comparisons did not find statistically significant differences.
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3 Downgraded by 1 for serious imprecision: The number of events in these trials was very low and the trials were underpowered to detect
differences. Although the meta-analysis result is statistically significant, the 95% CI is wide and includes clinically important effects and
unimportant effects.
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D I S C U S S I O N
Summary of main results
Overall, antimicrobial therapy shortened the mean duration of di-
arrhoea by about a day and a half compared to placebo or no treat-
ment (moderate quality evidence). It also reduced the total stool vol-
ume by 50% (moderate quality evidence) and reduced the amount
of rehydration fluids required by 40% (moderate quality evidence).
In addition, antimicrobial therapy reduced the mean duration of
fecal excretion of vibrios by almost three days (moderate quality
evidence). In the presence of adequate supportive care, no deaths
were reported in all trials.
There was significant heterogeneity in the magnitude of these
benefits, however, attributed to the effect of three main variables.
These variables are: 1) allocation concealment, with trials at low
risk of selection bias having smaller effects; 2) time point for out-
come assessment, with trials with longer intervals between assess-
ments demonstrating greater effects; and 3) the type of antimicro-
bial, with tetracycline appearing to have larger biological effects
than other antibiotics.
The analysis of different antimicrobials included many compar-
isons (Figure 3).Tetracycline was the antibiotic most commonly
compared to placebo/no treatment, and in indirect comparisons
appeared to have larger effects compared to placebo than other an-
tibiotics. However, in head-to-head comparisons tetracycline did
not demonstrate significant benefits on either diarrhoea duration
or stool volume compared to doxycycline (low quality evidence), or
ciprofloxacin or norfloxacin (moderate quality evidence). Azithro-
mycin has not been compared directly to placebo or tetracycline.
However, single dose azithromycin shortened the duration of di-
arrhoea by over a day compared to ciprofloxacin (moderate quality
evidence) and by half a day compared to erythromycin (moderate
quality evidence). Quinolones in general were not more effective
than other antibiotics.
When evaluating duration of treatment, long duration (> 24
hours) reduced the duration of pathogen secretion, and reduced
rates of bacteriological failure (low quality evidence), but for clin-
ical outcomes short and long treatment duration did not differ
significantly.
Overall completeness and applicability of
evidence
The above benefits of antibiotics should be considered valid when
treating people infected with V. cholera strains that are susceptible
to the antibiotics used, as was the case in these primary studies.
The majority of included trials are now over 20 years old, and
bacterial susceptibility is dynamic and may increase or decrease
over time dependant on factors such as antibiotic consumption and
the emergence of new serotypes. Therefore, some of the included
antibiotics may not currently be relevant, due to resistance, but
may become relevant again in the future if reversal of resistance
occurs, as has been described for tetracycline (Faruque 2007). In
the ongoing outbreak in Mexico for example, the V. cholera strain
has reduced susceptibility to quinolones and is resistant to TMP-
SMX, but is susceptible to tetracycline and chloramphenicol (
WHO 2013).
Currently, the WHO recommends antimicrobial treatment only
for patients with severe dehydration (WHO2004), andmost trials
(70%) included in our review mandated some measure of sever-
ity at baseline. However, the percentage of patients with severe
dehydration at baseline (when reported) ranged between 0% and
100%, and our sub-group analysis at the trial level found similar
or larger effects in those trials recruiting patients with a mixed
severity of dehydration. This suggests that the benefits of antibi-
otics extends to patients without severe dehydration.
Stratifying analyses by age revealed no differences in effects be-
tween children and adults. However, only a few trials included just
children and thus the current evidence applies mostly to adults.
The trials included mostly male participants for technical reasons
(stool collection). Although the evidence resulting from these trials
directly applies to male patients, we cannot think of any biological
reason why antimicrobial therapy should have different effects in
males and females.
The effect of antimicrobial treatment on resistance development
was not assessed in these studies. In any case, randomized con-
trolled trials are probably not the optimal platform to examine
resistance development in cholera.
Quality of the evidence
Risk of bias relating to allocation concealment affected the magni-
tude of effect in comparisons between antimicrobials and placebo/
no treatment, with the benefits of antimicrobials exaggerated in
trials at high risk for bias. We downgraded the quality of evidence
for this comparison based on limitations in the designs for these
trials. However, a highly significant benefit was observed in the
subgroup of trials at low risk for bias regarding allocation con-
cealment for all outcomes, thus our GRADE classifications were
conservative. We did not conduct sensitivity analyses for other
methodological limitations of the studies, such as blinding, be-
cause the objectively-assessed outcomes included in our review are
relatively resistant to bias once the patient is allocated to one of
the study arms (Wood 2008).
Potential biases in the review process
Many trials did not report V. cholerae susceptibility to the antibi-
otics being tested. Where reported, resistance rates were low; in
rare cases, where V. cholerae isolates were resistant to the tested
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antibiotic, we excluded this arm. Our assumption is that, at the
time of the trial, resistance to the tested antibiotics was low.
The outcomes of stool volume and requirements for rehydration
fluids were reported in different units of measurement in the stud-
ies included in our review: either total amount in litres or in mL/
kg bodyweight. Although the latter is the more appropriate way
of presenting these outcomes, only few trials reported weight-ad-
justed results. For both outcomes, the distribution of data was
skewed. Meta-analysis of the (log) ratio of means (or imputed
means) served us well in overcoming some of the problems of
summarizing non-normally distributed continuous data. It has
been shown empirically that ratio ofmeansmeta-analysis produces
treatment effects similar to difference-based methods (Friedrich
2011). While these results should be viewed with caution, we be-
lieve they are more informative than merely describing the out-
comes of individual trials.
We performed several indirect comparisons to complement direct
randomized comparisons, which were usually based on few trials.
Indirect comparisons are non-randomized and compare antibi-
otics used in different settings and circumstances, and thus should
be viewed with caution.
Agreements and disagreements with other
studies or reviews
It is generally agreed that antimicrobial therapy helps shorten the
duration of disease and should thus be used. In their review, Sack
2004 estimated that a one to three day course of antimicrobials
shortens recovery time from four to five days to two to three days.
Ours is the first systematic review to provide absolute figures for
this and other outcomes. This quantification can assist health of-
ficials in policy decisions and help develop transmission models
for cholera epidemics, such as the ones proposed for the epidemic
in Haiti (Andrews 2011; Tuite 2011).
Tetracycline and azithromycin appear to have advantages over
other antibiotics and a possible explanation for this could be their
mechanism of action. Both of these antimicrobials inhibit protein
synthesis and so may directly inhibit the synthesis of the protein
enterotoxin responsible for cholera symptoms.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current evidence supports the use of antibiotics to reduce the
duration and severity of cholera, and to reduce the duration of
pathogen excretion. The benefits shown in this review are relevant
to the treatment of individual patients, but theymay also extend to
other patients by curtailing pathogen excretion and so interrupting
transmission during epidemics.
While patients with severe dehydration are most at risk of death,
the benefits of antibiotics probably extend to those with less se-
vere degrees of dehydration. Treatment of these groups during
epidemics may also help to ease pressure on health services and
decrease transmission.
The choice of antibiotic will depend on the drug susceptibility of
the epidemic strain, but the evidence supports the use of tetracy-
cline or azithromycin when isolates are susceptible to these antibi-
otics.
Implications for research
Trials assessing the efficacy of antimicrobial treatment among
cholera patients with mild or no dehydration are needed. These
and other studies (randomized or observational) should attempt
to examine the effects of antimicrobial treatment on the spread
of cholera and on outbreak containment. Since resistance of V.
cholerae to antimicrobials is an issue of great importance and rising
concern, future trials should monitor and report on resistance de-
velopment in persisting isolates and on baseline resistance profiles
throughout the duration of the trial. In this review, we have shown
the effect of bias in randomized controlled trials on results. Future
trials should adhere to low-risk allocation concealment methods
for randomization and include women as well as men.
A trial comparing azithromycin with tetracycline, both given for
the same effective duration (eg single dose azithromycin versus
three to four days of tetracycline) would be interesting, since
azithromycin has so far only been compared with erythromycin
and ciprofloxacin given for shorter durations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alam 1990 BGD
Methods Randomized controlled trial.
Follow up duration: until faecal cultures were negative for two consecutive days
Participants Location: Dhaka, Bangaladesh.
Years: 1986 to 1987.
Participants: age > 15 yrs; 40% females.
Number of participants: 261 randomized, 246 evaluated.
Cholera serogroup: O1 (biotype: El-tor, classical).
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 500 mg four times per day for 2 days.
PO Doxycycline: 300 mg single dose.
PO Doxycycline: 200 mg single dose.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: duration of diarrhoea from entry to study until
8 hours have passed since last watery stool)
Stool volume in mL/kg body weight (defined as: volume of diarrhoea from entry to study
until last watery stool)
Bacteriological failure (defined as: number of patients with V. cholerae in stool on day 3
of study).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, glucose ORS.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Number code kept in WHO headquarters
in Geneva (thus assumed code is random)
Allocation concealment (selection bias) Low risk Sealed numbered envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 15 out of 261 patients were not eval-
uated, reasons were not specified
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Alam 1990 BGD (Continued)
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 15 out of 261 patients were not eval-
uated, reasons were not specified
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Unclear risk Study sponsor: academic. Drugs provided
by Pfizer.
Bhattacharya 1990 IND
Methods Randomized controlled trial.
Follow up duration: not specified, probably while in hospital
Participants Location: Kolkata, India.
Years: not specified.
Participants: age > 18 yrs. No females participated.
Number of participants: 78 randomized, 37 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Norfloxacin: 400 mg twice per day for 5 days.
PO TMP-SMX: (Trimetoprim: 160 mg; Sulfamethoxazol: 800 mg) twice per day for 5
days
PO Placebo: 1 Tab. twice per day for 5 days.
Resistance to intervention: 100% resistance to TMP-SMX, 0% resistance toNorfloxacin
Outcomes Diarrhoea duration in hours (definition not specified).
Total stool volume in litres (definition not specified in study)
Deaths (definition not specified in study, probably while in hospital)
Bacteriological failure (defined as: number of patients with V. cholerae in stool on day 3
of study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS according to WHO recommenda-
tions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
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Bhattacharya 1990 IND (Continued)
Allocation concealment (selection bias) Low risk Identical pills coded according to a code
that was opened after completion of the
study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk Approximately 50% of the patients in each
group were not evaluated, reasons were not
specified
Incomplete outcome data (attrition bias)
Stool volume
High risk Approximately 50% of the patients in each
group were not evaluated, reasons were not
specified
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias High risk Study sponsor: academic, Ranbaxy Labo-
ratories Ltd.
Bhattacharya 2003 IND
Methods Randomized controlled trial.
Follow up duration: not specified, probably while in hospital
Participants Location: Kolkata, India.
Years: 2000 to 2002.
Participants: children. No females participated.
Number of participants: 80 randomized, 56 evaluated.
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions POAzithromycin: 10mg/kg once per day for 3days; POplacebomatchingErythromycin
PO Erythromycin: 12.5 mg/kg four times per day for 3 days; PO placebo matching
Azithromycin
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (definition not specified).
Total stool volume in litres (definition not specified in study)
Deaths (full recovery stated for all study participants).
Bacteriological failure (all patients stopped secreting vibrios in stool within first day of
treatment)
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS according to WHO recommenda-
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Bhattacharya 2003 IND (Continued)
tions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table (using block ran-
domizations of various block lengths)
Allocation concealment (selection bias) Low risk Sealed numbered envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 11 out of 40 in the azithromycin group and
13 out of 40 in the erythromycin group
were not evaluated, reasons were not spec-
ified
Incomplete outcome data (attrition bias)
Stool volume
High risk 11 out of 40 in the azithromycin group and
13 out of 40 in the erythromycin group
were not evaluated, reasons were not spec-
ified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias Unclear risk Sponsor not stated.
Burans 1989 SOM
Methods Randomized controlled trial.
Follow up duration: not specified, while in hospital.
Participants Location: Mogadishu, Somalia.
Years: not specified.
Participants: children and adults. Female participation not specified
Number of participants: 47 randomized, 47 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Erythromycin: adults 800 mg; children 20 mg/kg twice per day until discharge
POTMP-SMX: (adults: Trimetoprim 160mg, Sulfametoxazol 800 mg; children: Trime-
toprim 4 mg/kg; Sulfametoxazol 20 mg/kg) twice per day until discharge
PO Dextrose (as placebo): twice per day until discharge.
Resistance to intervention: 2% resistance to TMP-SMX, 0% resistance to Erythromycin
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Burans 1989 SOM (Continued)
Outcomes Diarrhoea duration in days (definition not specified).
Bacteriological failure (no. of patients with stool free of vibrios after 24, 48, and 72
hours)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Placebo was used, but it was cherry
flavoured.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk All patients randomized to each group were
evaluated.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk Study sponsor: academic.
Butler 1993 Multi-Center
Methods Randomized controlled trial.
Follow up duration: 5 days.
Participants Location: multicenter (Thailand, Indonesia, Ivory coast, Mexico, Israel, Italy)
Years: 1987 to 1989.
Participants: adults. Female participation not specified.
Number of participants: 508 randomized, 46 evaluated.
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: yes.
Interventions PO Fleroxacin: 400 mg once per day for 3 days.
PO Fleroxacin: 400 mg single dose; PO placebo once per day for the next two days
PO Placebo: once per day for 3 days.
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Butler 1993 Multi-Center (Continued)
Resistance to intervention: no resistance.
Outcomes Clinical failure (defined as: continuation of diarrhoea over 48 hours since beginning of
treatment)
Bacteriological failure (defined as: stool culture positive for V. cholerae on day 3 of study)
.
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers generated by a com-
puter.
Allocation concealment (selection bias) Low risk Number code was not revealed to investi-
gators until the study ended
Blinding (performance bias and detection
bias)
All outcomes
Low risk Doubel blind. All patients received identi-
cal looking pills, in the same amount
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Unclear risk Study sponsor:manufacturer of Fleroxacin.
Carpenter 1964 IND
Methods Quasi-randomized controlled trial.
Follow up duration: at least 7 days.
Participants Location: Kolkata, India.
Years: 1963.
Participants: adults. No females participated.
Number of participants: 20 randomized, 20 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: no.
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Carpenter 1964 IND (Continued)
Interventions IV Tetracycline: 100 mg four times per day for the first day. PO Tetracycline: 500 mg
four times per day for 3 days
No treatment.
Resistance to intervention: not specified.
Outcomes Total stool volume in litres (definition not specified in study)
Deaths (defined as number of deaths during follow up, information obtained from
correspondence with the author)
Pathogen secretion duration in days (defined as number of days with a positive culture
for V. cholerae).
Clinical failure (defined as number of patients with stool volume > 3450 mL/day after
72 hours of treatment)
Bacteriological failure (defined as: stool culture positive for V. cholerae after 48 and 72
hours of treatment).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, water, barley water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The first patient to arrive received no an-
tibiotics and the second received Tetracy-
cline
Allocation concealment (selection bias) High risk Patients received treatment according to
time of arrival at the hospital
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm received no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Low risk All randomized patients were evaluated.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk Study sponsor: academic.
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Chaud 1968 IND
Methods Randomized controlled trial.
Follow up duration: while in hospital, average of 7 days.
Participants Location: Kolkata, India.
Years: not specified.
Participants: adults. No females participated.
Number of participants: 72 randomized, 72 evaluated. Stool positive for V. cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: no.
Interventions PO Forazolidone: 100 mg four times per day for 3 days.
PO Forazolidone: 400 mg once per day for 3 days.
PO Tetracycline: 250 mg four times per day for 3 days.
Resistance to intervention: not specified.
Outcomes Deaths (full recovery stated for all study participants).
Bacteriological failure (defined as: vibrios in stool after 48 hours from beginning of
treatment)
Bacteriological relapse (defined as: positive rectal swab after a negative one)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk Study sponsor: academic.
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De 1976 IND
Methods Randomized controlled trial.
Follow up duration: not specified, probably while in hospital
Participants Location: Kolkata, India.
Years: 1975.
Participants: children and adults. No females participated.
Number of participants: number randomized not specified, 76 evaluated
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Doxycycline: adults 200 mg single dose first day, 100 mg single dose second day;
children 4 mg/kg single dose first day, 2 mg/kg single dose second day
PO Doxycycline: adults 200 mg single dose; children 4 mg/kg single dose
PO Doxycycline: adults 300 mg single dose; children 6 mg/kg single dose
PO Tetracycline: adults 500 mg four times per day; children 250 mg four times per day
for 2 days
Resistance to intervention: not specified.
Outcomes Diarrhoea duration in hours (defined as: time until the appearance of semisolid stools)
Total fluid output in litres (definition not specified in study)
Deaths (during follow up).
Pathogen secretion duration in hours (definition not specified in study)
Bacteriological failure (defined as: vibrios in stool after 48 hours from beginning of
treatment)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, plain water.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
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De 1976 IND (Continued)
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Unclear risk Study sponsor: academic, WHO, Pfizer
supplied the Doxycycline
Dutta 1996 IND
Methods Randomized controlled trial.
Follow up duration: 5 days.
Participants Location: Kolkata, India.
Years: 1993 to 1994.
Participants: adults. No females participated.
Number of participants: 160 randomized, 111 evaluated.
Cholera serogroup: O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Doxycycline: 300 mg single dose.
PO Norfloxacin: 400 mg twice per day for 3 days.
PO Norfloxacin: 800 mg single dose.
No treatment.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: time until passage of last unformed stool)
Total fluid output in litres (definition not specified in study)
Deaths (during follow up).
Bacteriological failure (defined as: continued excretion of V. cholerae O139 in stool at
day 3).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS according to WHO recommenda-
tions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts. Outcome assessor was blinded
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Dutta 1996 IND (Continued)
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 11 to 14 patients out of 40 in each group
were not evaluated for the outcome, reasons
were not specified
Incomplete outcome data (attrition bias)
Stool volume
High risk 11 to 14 patients out of 40 in each group
were not evaluated for the outcome, reasons
were not specified
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Unclear risk Study sponsor: academic.
Francis 1971 NGA
Methods Randomized controlled trial.
Follow up duration: 23 days.
Participants Location: Ibadan, Nigeria.
Years: not specified.
Participants: age > 10 years. Female participation not specified
Number of participants: number randomized not specified, 65 evaluated. Stool positive
for V. cholerae required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Fanasil: 2 g single dose. Followed by PO Dextrose (as placebo) twice per day for 3
days
PO Tetracyclime: 500 mg four times per day for 3 days.
PO TMP-SMX: (Trimetoprim 160 mg, Sulfametoxazol 900 mg) bid for 3 days
PO Dextrose (as placebo) bid for 3 days.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in days (defined as: number of days until the patients ceased to pass
more than 2 stools per day)
Pathogen secretion duration in days (definition not specified in study)
Clinical failure (defined as: more than 2 stools per day on day 2 or 3 of the study)
Bacteriological failure (defined as: continued excretion of V. cholerae in stool at day 2 or
3 of study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, ORS type not specified
Early stop: Placebo and Fanasil arms were stopped early.
Risk of bias
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Francis 1971 NGA (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding broken, two arms were stopped
early.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
Gharagozoloo 1970 IRN
Methods Randomized controlled trial.
Follow up duration: until faecal cultures were negative for three consecutive days
Participants Location: Teheran, Iran.
Years: not specified.
Participants: children and adults. Female participation not specified
Number of participants: number randomized not specified, 42 evaluated
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: not specified.
Interventions PO Chloramphenicol: 12.5 mg/kg (maximal dose 500 mg) four times per day for a
minimum of 3 days (or until stool culture negative)
PO Tetracycline: 10 mg/kg (maximal dose 500 mg) four times per day for a minimum
of 3 days (or until stool culture negative)
PO TMP-SMX: (Trimetoprim 5 mg/kg maximal dose 195 mg, Sulfametoxazol 25 mg/
kg maximal dose 800 mg) bid for a minimum of 3 days (or until stool culture negative)
PO Dextrose (as placebo): twice per day for a minimum of 3 days (or until stool culture
negative)
Resistance to intervention: not specified.
Outcomes Bacteriological failure (defined as: stool positive for V. cholerae after day 2 of study).
Bacteriological relapse (defined as: re-appearance of V. cholerae in stool after initial erad-
ication).
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Gharagozoloo 1970 IRN (Continued)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk Study sponsor: academic.
Gotuzzo 1995 PER
Methods Randomized controlled trial.
Follow up duration: 4 days.
Participants Location: Lima, Peru.
Years: 1992 to 1993.
Participants: adults aged 18 to 65 years; 35% females.
Number of participants: 214 randomized, 202 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Ciprofloxacin: 250 mg once per day for 3 days. PO placebo matching Tetracycline
PO Tetracycline: 500 mg four times per day for 3 days. PO placebo matching Ciproflo-
xacin
Resistance to intervention: no resistance.
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Gotuzzo 1995 PER (Continued)
Outcomes Diarrhoea duration in hours (defined as: time from initial administration of study drug
to the last liquid stool passed)
Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: diarrhoea on day 2 or 3 of study)
Bacteriological failure (defined as: stool positive for V. cholerae after day 3 of study).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS according to the WHO recom-
mendations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random table with fixed blocks of ten.
Allocation concealment (selection bias) Low risk Envelopes labelled onlywith study number.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 7 out of 107 in the ciprofloxacin
group and 5 out of 107 in the tetracycline
group were not evaluated, reasons were not
specified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 7 out of 107 in the ciprofloxacin
group and 5 out of 107 in the tetracycline
group were not evaluated, reasons were not
specified
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias High risk Study sponsor: Bayer.
Grados 1996 PER
Methods Randomized controlled trial.
Follow up duration: 5 days.
Participants Location: Lima, Peru.
Years: 1993.
Participants: age > 15 years; 32% females.
Number of participants: number randomized not specified, 107 evaluated. Stool positive
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Grados 1996 PER (Continued)
for V. cholerae required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO TMP-SMX: (Trimetoprim 160 mg, Sulfametoxazol 800 mg) twice per day for 3
days
PO Tetracycline: 500 mg four times per day for 3 days.
Resistance to intervention: 7% resistance to tetracycline.
Outcomes Diarrhoea duration in hours (defined as: time from initial administration of study drug
until stool output < 400 mL/hour)
Clinical failure (defined as: diarrhoea output above 400 mL/hour until discharged)
Bacteriological failure (defined as: stool positive for V. cholerae 48 hours after completing
treatment).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk Study sponsor: academic.
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Hossain 2002 BGD
Methods Randomized controlled trial.
Follow up duration: until faecal cultures were negative for two consecutive days
Participants Location: Dhaka, Bangladesh.
Years: 1993.
Participants: adults. No females participated.
Number of participants: 50 randomized, 43 evaluated. Stool positive for V. cholerae
required for inclusion.
Cholera serogroup: O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 500 mg four times per day for 3 days.
PO placebo: four times per day for 3 days.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: time from initial administration of study drug
until the end of the last 8-hour period when a liquid stool has been passed)
Stool volume in mL/kg (defined as: volume of stool in the 72 hours following the first
administration of study drug)
Pathogen secretion duration in days (definition not specified in study)
Clinical failure (defined as: continuation of diarrhoea after 72 hours from initiation of
study drug)
Bacteriological failure (defined as: V. cholerae in stool after 72 hours from initiation of
study drug).
Clinical relapse (defined as: initial resolution of diarrhoea followed by passage of liquid
stool anytime during the study)
Bacteriological relapse (defined as: a positive culture following a negative stool sample
that was obtained 72 hours after initiation of study drug)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, rice-based ORS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated number list.
Allocation concealment (selection bias) Low risk Randomization list kept with a researcher
not involved in the study, pharmacist sup-
plied drug by number
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
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Hossain 2002 BGD (Continued)
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 4 out of 25 patients in the tetracycline
group and 3 out of 25 in the placebo group
were not evaluated, reasons were not spec-
ified
Incomplete outcome data (attrition bias)
Stool volume
High risk 4 out of 25 patients in the tetracycline
group and 3 out of 25 in the placebo group
were not evaluated, reasons were not spec-
ified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias Low risk Study sponsor: academic.
Islam 1987 BGD
Methods Randomized controlled trial.
Follow up duration: not specified.
Participants Location: Dhaka, Bangladesh.
Years: not specified.
Participants: adults; 46% females.
Number of participants: 125 randomized, 118 evaluated. Stool positive for V. cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 1 g single dose.
PO Tetracycline: 2 g single dose.
PO Tetracycline: 500 mg four times per day for 1 day.
No treatment.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: time until the end of the last 8 hour period in
which liquid stool was passed)
Stool volume in mL/kg (definition not specified in study).
Pathogen secretion duration in days (definition not specified in study)
Bacteriological failure (defined as: V. cholerae in stool after 48 or 72 hours).
Clinical relapse (defined as: the return of liquid stool after passing solid stool)
Bacteriological relapse (defined as: a patient who became bacteriologically negative for
at least two consecutive days and was subsequently positive for V. cholerae).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
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Islam 1987 BGD (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk Notes drawn from an envelope, not stated
whether sealed and opaque
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 5 out of 50 in the SD1 group and 2
out of 25 in the SD2 group were not eval-
uated, all patients in the tetracycline and
control group were evaluated. Reasons for
inclusion were not specified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 5 out of 50 in the SD1 group and 2
out of 25 in the SD2 group were not eval-
uated, all patients in the tetracycline and
control group were evaluated. Reasons for
inclusion were not specified
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
Kabir 1996 BGD
Methods Randomized controlled trial.
Follow up duration: 5 days minimum.
Participants Location: Dhaka, Bangladesh.
Years: 1991 to 1992.
Participants: children aged 1 to 8 years. No females participated
Number of participants: 54 randomized, 48 evaluated. Stool positive for V. cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Erythromycin: 12.5 mg/kg four times per day for 5 days.
PO TMP-SMX: (Trimetoprim 5 mg/kg, Sulfametoxazol 25 mg/kg) twice per day for 5
days
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Kabir 1996 BGD (Continued)
No treatment.
Resistance to intervention: 23% resistance to Erythromycin and TMP-SMX
Outcomes Diarrhoea duration in hours (defined as: time until the end of the last 8 hour period in
which liquid stool was passed)
Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: duration of diarrhoea which exceeded 72 hours)
Bacteriological failure (defined as: V. cholerae in stool after day 3 of study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, rice-based ORS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Sealed envelopes containing the treatment
code.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 6 out of 54 patients randomized were not
evaluated, reasons were not specified
Incomplete outcome data (attrition bias)
Stool volume
High risk 6 out of 54 patients randomized were not
evaluated, reasons were not specified
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Low risk Study sponsor: academic.
Karchmer 1970 PAK
Methods Quasi-randomized controlled trial.
Follow up duration: 14 days.
Participants Location: Dacca, Pakistan.
Years: 1966.
Participants: children; 51% females.
Number of participants: number randomized not specified, 78 evaluated
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
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Exclusion due to severity of symptoms: not specified.
Interventions PO Furazolidone: 1.25 mg/kg four times per day for 7 days.
PO Tetracycline: 2.5 mg/kg four times per day for 7 days.
PO Tetracycline: 7.75 to 15.25 mg/kg four times per day for 7 days
No treatment.
Resistance to intervention: not specified.
Outcomes Diarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour
period in which liquid stool was passed)
Stool volume in litres (definition not specified in study).
Pathogen secretion duration in days (definition not specified in study)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk According to day of admission.
Allocation concealment (selection bias) High risk Treatment allocated by day of week.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
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Kaushik 2010 IND
Methods Randomized controlled trial.
Follow up duration: 7 days.
Participants Location: Delhi, India.
Years: 2006 to 2007.
Participants: Children aged 2 to 12 years; 43% female.
Number of participants: 407 randomized, 180 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: yes.
Interventions PO Azithromycin: 20 mg/kg single dose.
PO Ciprofloxacin: 20 mg/kg single dose.
Resistance to intervention: 0.6% resistance to Ciprofloxacin. Resistance to Azithromycin
not specified
Outcomes Diarrhoea duration hours (defined as: time from entry to study until resolution of
diarrhoea)
Pathogen secretion duration in hours (definition not specified in study)
Clinical failure (defined as: continuation of diarrhoea after 72 hours from the beginning
of therapy)
Bacteriological failure (defined as: V. cholerae in stool on day 3 of the study).
Clinical relapse (defined as: cessation of diarrhoea for one day or longer, followed by the
return of diarrhoea)
Bacteriological relapse (defined as: positive stool culture following a negative one)
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS (type unspecified)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Identical sealed envelopes, opened only af-
ter enrolment.
Blinding (performance bias and detection
bias)
All outcomes
High risk Different pills, both given single dose
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 114 out of 205 in the azithromycin group
and 113 out of 202 in the ciprofloxacin
group were not evaluated, reasons were not
specified
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Kaushik 2010 IND (Continued)
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk No sponsor.
Khan 1995a BGD
Methods Randomized controlled trial.
Follow up duration: 3 days.
Participants Location: Dhaka, Bangladesh.
Years: not specified.
Participants: adults. No females participated.
Number of participants: 64 randomized, 63 evaluated.
Cholera serogroup: O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 500 mg four times per day for 3 days.
PO Erythromycin: 500 mg four times per day for 3 days.
PO Ciprofloxacin: 1 g single dose.
PO Doxycycline: 300 mg single dose.
Resistance to intervention: not specified.
Outcomes Diarrhoea duration in hours (defined as: time from administration of study drug until
the end of the last 8 hour period in which liquid stool was passed)
Stool volume in mL/kg (definition not specified in study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
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Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk All patients, with the exception of 1 out of
16 in the erythromycin group, were evalu-
ated
Incomplete outcome data (attrition bias)
Stool volume
Low risk All patients, with the exception of 1 out of
16 in the erythromycin group, were evalu-
ated
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
Khan 1995b BGD
Methods Randomized controlled trial.
Follow up duration: 3 to 5 days.
Participants Location: Dhaka, Bangladesh.
Years: 1992.
Participants: adults. No females participated.
Number of participants: 75 randomized, 72 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Ciproflixacin: 500 mg twice per day for 3 days.
PO Erythromycin: 500 mg four times per day for 3 days.
PO Nalidixic acid: 500 mg four times per day for 3 days.
PO Pivmecillinam: 400 mg four times per day for 3 days.
PO Tetracycline: 500 mg four times per day for 3 days.
Resistance to intervention: 75% resistance to Tetracycline in all arms; 100% resistance
to Tetracycline in the Tetracycline arm
Outcomes Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea after 72 hours of treatment)
Bacteriological failure (defined as: V. cholerae in stool after day 2 or 3 of study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomizedmethodwith a block size
of 10.
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Khan 1995b BGD (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Low risk All patients, with the exception of 3 out of
15 in the tetracycline group, were evaluated
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
Khan 1996 BGD
Methods Randomized controlled trial.
Follow up duration: 12 days.
Participants Location: Dhaka and rural Matlab district, Bangladesh.
Years: 1993 to 1995.
Participants: adults. No females participated.
Number of participants: 272 randomized, 260 evaluated.
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions O1 group:
PO Ciproflixacin: 1 g single dose. PO placebo matching Doxycycline
PO Doxycycline: 300 mg single dose. PO placebo matching Ciproflixacin
O139 group:
PO Ciproflixacin: 1 g single dose. PO placebo matching Doxycycline
PO Doxycycline: 300 mg single dose. PO placebo matching Ciproflixacin
Resistance to intervention: one O1 strain isolated which was resistant to Doxycycline
Outcomes Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea after 48 or 72 hours of treatment)
Bacteriological failure (defined as: V. cholerae in stool after day 2 or 3 of study).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated list, randomization
blocks of 10.
Allocation concealment (selection bias) Low risk Patients were consecutively assigned num-
bers, perilously allocated to treatment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 12 out of 272 were not evaluated,
reasons were not specified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 12 out of 272 were not evaluated,
reasons were not specified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias High risk Study sponsor: academic, Bayer, Pfizer sup-
plied drugs.
Khan 2002 BGD
Methods Randomized controlled trial.
Follow up duration: 12 days.
Participants Location: Dhaka and rural Matlab district, Bangladesh.
Years: 1999.
Participants: children aged 1 to 15 years. No females participated
Number of participants: 128 randomized, 123 evaluated.
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Azithromycin: 20 mg/kg (maximal individual dose: 1 g) single dose. PO placebo
matching Erithromycin
PO Erithromycin: 12.5 mg/kg (maximal individual dose: 500 mg) four times per day
PO placebo matching Azithromycin
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: interval between administration of study drug
to the end of the last 6 hours period in which patient passed a watery stool)
Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea after 48 or 72 hours of treatment)
Bacteriological failure (defined as: V. cholerae in stool after day 2 of study).
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Clinical relapse (defined as: re-appearance of diarrhoea after discharge)
Bacteriological relapse (defined as: positive culture on day 7 after discharge)
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list using a block ran-
domization method with a block size of
four, stratified by site
Allocation concealment (selection bias) Low risk Patientswere consecutively assigned a study
number and provided study treatment that
had been randomly pre-assigned to that
number. List kept centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills. Out-
come assessor also blinded
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 2 out of 65 in the azithromycin group
and 3 out of 63 in the erythromycin group
were not evaluated, reasons were not spec-
ified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 2 out of 65 in the azithromycin group
and 3 out of 63 in the erythromycin group
were not evaluated, reasons were not spec-
ified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias High risk Study sponsor: academic, Pfizer.
Lapeysonnie 1971 CIV
Methods Randomized controlled trial.
Follow up duration: 8 days.
Participants Location: Godoume, Cote d’Ivoire.
Years: 1970.
Participants: children and adults. Female participation not specified
Number of participants: number randomized not specified, 37 evaluated
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Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: no.
Interventions PO Sulfometoxine: dose according to age, adult dose 2 g single dose
PO Pyridoxine as placebo: dose according to age single dose.
Resistance to intervention: not stated.
Outcomes Clinical failure (defined as: no definitive disappearance of diarrhoea on day 3 or 5 of
study)
Notes Ethics committee involved: not specified.
Consent requested and given from study participants: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description
Allocation concealment (selection bias) Unclear risk No description
Blinding (performance bias and detection
bias)
All outcomes
High risk Stated as double blind, but patients re-
ceived different pills in different amounts
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) High risk Study reported on different outcomes in
the results than previously specified in the
methods
Other bias Unclear risk Ethics committee involved: not specified.
Consent requested and given from study
participants: not specified
Type of hydration used in study: IV hydra-
tion, ORS type not specified
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Lindenbaum 1967a PAK
Methods Quasi-randomized controlled trial.
Follow up duration: until stools were negative for V. cholerae for 3 consecutive days.
Participants Location: Dacca, Pakistan.
Years: 1964 to 1966.
Participants: adults; 34% females.
Number of participants: number randomized not specified, 313 evaluated. Stool positive
for V.cholerae required for inclusion.
Cholera serogroup: Not specified (probably O1).
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 250, 500 or 750 mg four times per day for 2, 3 or 4 days
PO Chloramphenicol: 250, 500 or 750 mg four times per day for 2 or 3 days
PO Streptomycin: 1 g four times per day for 2 or 3 days.
PO Paromomycin: 250 or 500 mg four times per day for 2 or 3 days
No treatment.
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour
period in which liquid stool was passed)
Stool volume in litres (definition not specified in study).
Deaths during study (definition not specified in study).
Pathogen secretion duration in days (definition not specified in study)
Clinical failure (defined as: diarrhoea that lasted more than 4 days in treated patients)
Clinical relapse (defined as: passing formed stool and subsequently passing watery stool
enough to require resumption of IV hydration)
Bacteriological relapse (defined as: stool negative for at least one day and than positive
again)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration only.
Early stop: Streptomycin and Paromomycin arms were stopped early
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomization according to day of admis-
sion.
Allocation concealment (selection bias) High risk Treatment allocation according to day of
admission.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts and durations
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Lindenbaum 1967a PAK (Continued)
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Low risk No sponsor.
Lindenbaum 1967b PAK
Methods Quasi-randomized controlled trial.
Follow up duration: until stools were negative for V. cholerae for 3 consecutive days.
Participants Location: Dacca, Pakistan.
Years: 1964 to 1966.
Participants: children aged 6 weeks to 10 years; 46% females
Number of participants: 243 randomized, 238 evaluated. Stool positive for V.cholerae
required for inclusion.
Cholera serogroup: Not specified (probably O1).
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 125 or 250 mg four times per day for 2, 3 or 4 days
PO Chloramphenicol: 125, 250 or 500 mg four times per day for 2 or 3 days
PO Streptomycin: 500 mg four times per day for 2 or 3 days.
PO Paromomycin: 125 or 250 mg four times per day for 2 or 3 days
No treatment.
Resistance to intervention: not specified.
Outcomes Diarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour
period in which liquid stool was passed)
Stool volume in litres (definition not specified in study).
Pathogen secretion duration in days (definition not specified in study)
Clinical failure (defined as: diarrhoea that lasted more than 4 days in treated patients)
Clinical relapse (defined as: passing formed stool and subsequently passing watery stool
enough to require resumption of IV hydration)
Bacteriological relapse (defined as: stool negative for at least 1 day and then positive
again)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration only.
Early stop: Streptomycin and Paromomycin arms were stopped early
Risk of bias
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Lindenbaum 1967b PAK (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomization according to day of admis-
sion.
Allocation concealment (selection bias) High risk Treatment allocation according to day of
admission.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts and durations
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 5 out of 243 were not evaluated, rea-
sons were not specified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 5 out of 243 were not evaluated, rea-
sons were not specified
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Low risk No sponsor.
Lolekha 1988 THA
Methods Randomized controlled trial.
Follow up duration: 10 to 15 days.
Participants Location: Nohnburi, Thailand.
Years: 1986 to 1987.
Participants: adults; 51% females.
Number of participants: 450 randomized, 47 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: no.
Exclusion due to severity of symptoms: yes.
Interventions PO Norfloxacine: 400 mg twice per day for 3 days.
PO TMP-SMX: (Trimetoprim 160 mg, Sulfametoxazol 800 mg) twice per day for 3
days
PO placebo: twice per day for 3 days.
Resistance to intervention: 2% resistance to TMP-SMX.
Outcomes Duration of diarrhoea in hours (defined as: time from start of treatment until disappear-
ance of watery stools and no more than 3 stools per day)
Bacteriological failure (defined as: positive stool culture on day 4 of study)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
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Lolekha 1988 THA (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk Only a few of the patients randomized (14
to18 out of 150 in each group) were eval-
uated, reasons were not specified
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias High risk Study sponsor: academic, Astra Alab.
Mihindukulasurya 1976 LKA
Methods Randomized controlled trial.
Follow up duration: 5 days minimum.
Participants Location: Angoda, Sri Lanka.
Years: not specified.
Participants: adults; 45% females.
Number of participants: 20 randomized and evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: not specified (most probably O1).
Exclusion due to previous use of antibiotics: no.
Exclusion due to severity of symptoms: no.
Interventions PO Sulphadoxine: 2 g single dose.
PO Tetracycline: 500 mg four times per day for 3 days.
Resistance to intervention: no resistance.
Outcomes Stool volume in litres (definition not specified in study).
Bacteriological failure (defined as: V. cholerae in stool on day 2 or 3 of study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
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Mihindukulasurya 1976 LKA (Continued)
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts. Outcome assessor was blinded
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Low risk All patients randomized were evaluated.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk No sponsor.
Moolasarat 1998 THA
Methods Randomized controlled trial.
Follow up duration: not specified.
Participants Location: Bangkok, Thailand.
Years: 1994 to 1996.
Participants: children and adults; 48% females.
Number of participants: number randomized not specified, 25 evaluated
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: yes.
Interventions PO Tetracycline: adults 500 mg; children 12.5 mg/kg four times per day for 3 days
PO Norfloxacine: adults 400 mg; children 7.5 mg/kg twice per day for 3 days
Resistance to intervention: no resistance.
Outcomes Duration of diarrhoea (definition not specified in study).
Deaths (during study).
Pathogen secretion duration in days (definition not specified in study)
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Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different pills in different
amounts.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Time point for outcome assessment not de-
fined.
Other bias Low risk No sponsor.
Pierce 1968 IND
Methods Randomized controlled trial.
Follow up duration: not specified.
Participants Location: Kolkata, India.
Years: 1967.
Participants: adults. No females participated.
Number of participants: 65 randomized, 49 evaluated.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: adults 500 mg four times per day for 2 days
PO Furazolidone: 200 mg four times per day for 3 days.
PO Furazolidone: 400 mg once per day for 3 days.
No treatment.
Resistance to intervention: no resistance.
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Pierce 1968 IND (Continued)
Outcomes Duration of diarrhoea (defined as: time from entry to study until the last passage of any
liquid stool).
Stool volume in mL/kg (definition not specified in study).
Deaths (during study).
Pathogen secretion duration in hours (defined as: time from entry until the last positive
stool culture was obtained)
Clinical relapse (defined as: recurrence of diarrhoea after termination of therapy)
Bacteriological relapse (defined as: positive culture after 3 days with negative cultures)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, water, green coconut water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk Number of patients randomized to each
group was not specified. Data was evalu-
ated for only 49 patients out of a total of
65 patients participating
Incomplete outcome data (attrition bias)
Stool volume
High risk Number of patients randomized to each
group was not specified. Data was evalu-
ated for only 49 patients out of a total of
65 patients participating
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
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Rabbani 1989 BGD
Methods Randomized controlled trial.
Follow up duration: 7 days minimum.
Participants Location: Dhaka, Bangladesh.
Years: not specified.
Participants: adults. Female participation not specified.
Number of participants: 114 randomized, 87 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: yes.
Interventions PO Tetracycline: 1 g single dose.
PO Furazolidone: 400 mg single dose.
PO placebo: 2 tabs single dose.
Resistance to intervention: 13% resistance to Tetracycline; 22% resistance to Furazoli-
done
Outcomes Diarrhoea duration hours (defined as: time until the end of the last 8 hour period in
which liquid stool was passed)
Stool volume in litres (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea on day 4 or after)
Bacteriological failure (defined as: positive stool cultures 48 or 96 hours after treatment)
Clinical relapse (defined as: cure on day 4 with subsequent relapse)
Bacteriological relapse (defined as: stool positive for V cholerae on day 6).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, water.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers.
Allocation concealment (selection bias) Low risk Assuming the table was code: bottles con-
taining the drugs numerically coded, code
kept in New York and opened only after
the study had been completed
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 27 out of 114 were not evaluated, reasons
were not specified
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Incomplete outcome data (attrition bias)
Stool volume
High risk 27 out of 114 were not evaluated, reasons
were not specified
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias High risk Study sponsor: Norwich Eaton Pharma-
ceuticals.
Rabbani 1991 BGD
Methods Randomized controlled trial.
Follow up duration: not specified.
Participants Location: Dhaka, Bangladesh.
Years: 1985 to 1987.
Participants: children aged 1 month to 14 years; 28% females
Number of participants: number randomized not specified, 106 evaluated. Stool positive
for V .cholerae required for inclusion.
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: yes.
Interventions PO Furazolidone: 7 mg/kg single dose.
PO Furazolidone: 1.75 mg/kg four times per day for 3 days.
PO placebo: single dose.
PO placebo: four times per day for 3 days.
Resistance to intervention: 12% resistance to Furazolidone on the single dose arm; no
resistance to Furazolidone on the multiple dose arm
Outcomes Diarrhoea duration hours (defined as: time until the end of the last 8 hour period in
which liquid stool was passed)
Stool volume in litres (definition not specified in study).
Pathogen secretion duration in days (definition not specified in study)
Clinical failure (defined as: continuation of diarrhoea beyond 72 hours from the start of
treatment)
Bacteriological failure (defined as: stool cultures positive for V. cholerae on days 2, 3 or 4
after the start of treatment).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, water.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias High risk Study sponsor: Norwich-Eaton Pharma-
ceuticals, Inc.
Rahaman 1976 BGD
Methods Quasi-randomized controlled trial.
Follow up duration: not specified.
Participants Location: Dhaka, Bangladesh.
Years: 1974 to 1975.
Participants: children and adults. Female participation not specified
Number of participants: number randomized not specified, 51 evaluated
Cholera serogroup: not specified.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Doxycycline: adults 100 mg; children 2 mg/kg twice per day on the first day, once
per day on the next 3 days
PO Tetracycline: 5 mg/kg four times per day for 4 days.
PO placebo: administration manner not specified.
Resistance to intervention
Outcomes Diarrhoea duration hours (definition not specified in study)
Stool volume in litres (definition not specified in study).
Deaths (during study).
Pathogen secretion duration in days (definition not specified in study)
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, ORS type not specified
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Cards pre-arranged consecutively.
Allocation concealment (selection bias) High risk Cards pre-arranged consecutively; codes
held in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Placebo was used only to match Doxycy-
cline, not Tetracycline
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Unclear risk Study sponsor: academic, Pfizer supplied
placebo.
Roy 1998 BGD
Methods Randomized controlled trial.
Follow up duration: 4 days.
Participants Location: Dhaka, Bangladesh.
Years: not specified.
Participants: children aged 1 to 5 years. Female participation not specified
Number of participants: 184 randomized and evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Erythromycin: 12.5 mg/kg four times per day for 3 days.
PO Ampicillin: 12.5 mg/kg four times per day for 3 days.
PO Tetracycline: 6.5 mg/kg four times per day for 3 days.
PO placebo: four times per day for 3 days.
Resistance to intervention: 1% resistance to Ampicillin; 2% resistance to Erythromycin;
and 24% resistance to Tetracycline
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Outcomes Stool volume in litres (definition not specified in study).
Bacteriological failure (defined as: stool cultures positive for V. cholerae 48 hours after
the start of treatment).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, rice-based ORS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Outcome not reported.
Incomplete outcome data (attrition bias)
Stool volume
Low risk All patients randomized were evaluated.
Selective reporting (reporting bias) High risk Study outcomes were not specified at all in
the methods section
Other bias Low risk Study sponsor: academic.
Sack 1978 BGD
Methods Randomized controlled trial.
Follow up duration: until stools were negative for V. cholerae for 2 consecutive days.
Participants Location: Dhaka, Bangladesh.
Years: not specified.
Participants: children and adults. No females participated.
Number of participants: 74 randomized, 65 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
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Interventions PO Doxycycline: adults 200 mg; children 4 mg/kg single dose.
PO Doxycycline: adults 100 mg; children 2 mg/kg twice per day on the first day, once
per day on the next 3 days
Resistance to intervention: not specified.
Outcomes Stool weight in mg/kg (definition not specified in study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, water.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Predetermined list of random numbers.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients received different amounts of pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk 9 out of 74 patients randomized were not
evaluated, reasons were not specified
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Outcome not reported.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Unclear risk Study sponsor: academic. Pfizer Laboratory
measured serum levels
Saha 2005 BGD
Methods Randomized controlled trial.
Follow up duration: 6 weeks.
Participants Location: Dhaka and rural Matlab district, Bangladesh.
Years: 2001 to 2002.
Participants: children aged 2 to 15 years. Female participation not specified
Number of participants: 180 randomized, 162 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
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Interventions PO Ciprofloxacin: 20 mg/kg (maximal dose 750 mg) single dose
PO Erythromycin: 12.5 mg/kg (maximal dose 500 mg) four times per day for 3 days
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration in hours (defined as: time from the administration of study drug
until the end of the last 6 hour period without diarrhoea)
Stool volume in litres (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea after 48 hours from the adminis-
tration of study drug)
Bacteriological failure (defined as: stool cultures positive for V. cholerae after day 2 of
study).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, rice-based ORS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list prepared by indi-
viduals not otherwise involved in the study
with a block size of eight
Allocation concealment (selection bias) Low risk Sealed boxes opened after a patient had
been enrolled in the study and assigned a
study number
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients in different arms received different
amounts of medication
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 12 out of 90 patients in the cipro-
floxacin group and 6 out of 90 in the ery-
thromycin group were not evaluated, rea-
sons were not specified
Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 12 out of 90 patients in the cipro-
floxacin group and 6 out of 90 in the ery-
thromycin group were not evaluated, rea-
sons were not specified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias High risk Study sponsor: academic, Bayer AG.
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Saha 2006 BGD
Methods Randomized controlled trial.
Follow up duration: 12 to 15 days.
Participants Location: Dhaka, Bangladesh.
Years: 2002 to 2004.
Participants: adults. No females participated.
Number of participants: 198 randomized, 195 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: O1, O139.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Azithromycin: 1 g single dose; PO placebo matching Ciprofloxacin
PO Ciprofloxacin: 1 g single dose; PO placebo matching Azithromycin
Resistance to intervention: no resistance.
Outcomes Diarrhoea duration hours (defined as: time from administration of study drug until the
end of the last 6 hours period without diarrhoea)
Stool volume in mL/kg (definition not specified in study).
Clinical failure (defined as: continuation of diarrhoea after 48 hours from administration
of study drug)
Bacteriological failure (defined as: stool cultures positive for V. cholerae after 48 hours
from administration of study drug).
Notes Ethics committee involved: yes.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, rice-based ORS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomizations with a block of six
done by an independent researcher who
was not involved in the study
Allocation concealment (selection bias) Low risk Drugs and placebo were put in identical
bottles with sequential numbers according
to the randomized list
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, identical looking pills.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Low risk Only 2 out of 99 in the azithromycin group
and 1 out of 99 in the ciprofloxacin group
were not evaluated, the reasons were not
specified
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Incomplete outcome data (attrition bias)
Stool volume
Low risk Only 2 out of 99 in the azithromycin group
and 1 out of 99 in the ciprofloxacin group
were not evaluated, the reasons were not
specified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias Unclear risk Study sponsor: academic, Pfizer supplied
Azithromycin.
Usubutun 1997 TUR
Methods Randomized controlled trial.
Follow up duration: not specified.
Participants Location: Ankara, Turkey.
Years: 1994.
Participants: adults; 32% females.
Number of participants: 90 randomized, 74 evaluated. Stool positive for V .cholerae
required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: not specified.
Exclusion due to severity of symptoms: no.
Interventions PO Ciprofloxacin: 1 g single dose.
PO Ciprofloxacin: 500 mg twice per day for 1 day.
PO Doxycycline: 100 mg twice per day for 3 days.
No treatment.
Resistance to intervention: no resistance to Ciprofloxacin; resistance to Doxycycline not
specified
Outcomes Diarrhoea duration in days (defined as: time until day of study when patient did not
pass watery stool for 8 hours)
Stool volume in mL/kg (definition not specified in study).
Bacteriological failure (defined as: V. cholerae in stool after study day 4).
Clinical relapse (defined as: re-appearance of watery stool after a remission of 8 hours)
Bacteriological relapse (defined as: re-appearance of V. cholerae in stool after two negative
stool exams).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: yes.
Type of hydration used in study: IV hydration, ORS type not specified
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No description.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
High risk A relatively large number of patients in each
group (and a total of 16 out of 90) were not
evaluated, reasons were not specified
Incomplete outcome data (attrition bias)
Stool volume
High risk A relatively large number of patients in each
group (and a total of 16 out of 90) were not
evaluated, reasons were not specified
Selective reporting (reporting bias) Low risk Study outcomes were clearly specified and
reported.
Other bias Low risk No sponsor.
Wallac 1968˙A IND
Methods Randomized controlled trial.
Follow up duration: 7 days minimum.
Participants Location: Kolkata, India.
Years: 1965 to 1966.
Participants: adults. No females participated.
Number of participants: number randomized not specified, 33 evaluated. Stool positive
for V .cholerae required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 500 mg four times per day for 2 days.
PO Tetracycline: 250 mg four times per day for 3 days.
No treatment.
Resistance to intervention: not specified.
Outcomes Diarrhoea duration in hours (definition not specified in study)
Stool volume in litres (definition not specified in study).
Deaths (during study).
Pathogen excretion duration in days (definition not specified in study)
Clinical relapse (definition not specified in study).
Bacteriological relapse (definition not specified in study).
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Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, green coconut water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Previously randomized schedule.
Allocation concealment (selection bias) Unclear risk No description.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Low risk Study sponsor: academic.
Wallac 1968˙B IND
Methods Randomized controlled trial.
Follow up duration: 7 days minimum.
Participants Location: Kolkata, India.
Years: 1965 to 1966.
Participants: adults. No females participated.
Number of participants: number randomized not specified, 33 evaluated. Stool positive
for V .cholerae required for inclusion.
Cholera serogroup: O1.
Exclusion due to previous use of antibiotics: yes.
Exclusion due to severity of symptoms: no.
Interventions PO Tetracycline: 2 g once per day for 2 days.
PO Chloramphenicol: 500 mg four times per day for 3 days.
PO Sulfaguanidine: 500 mg every four hours for 2 days; 2 g three times per day for 5
days
No treatment.
Resistance to intervention: not specified.
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Wallac 1968˙B IND (Continued)
Outcomes Diarrhoea duration in hours (definition not specified in study)
Stool volume in litres (definition not specified in study).
Deaths (during study).
Pathogen excretion duration in days (definition not specified in study)
Clinical relapse (definition not specified in study).
Bacteriological relapse (definition not specified in study).
Notes Ethics committee involved: not specified.
consent requested and given from study participants: not specified
Type of hydration used in study: IV hydration, green coconut water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Treatment given alternately.
Allocation concealment (selection bias) High risk Treatment given alternately.
Blinding (performance bias and detection
bias)
All outcomes
High risk Control arm was given no treatment.
Incomplete outcome data (attrition bias)
Diarrhoea duration
Unclear risk Number of patients randomized was not
specified.
Incomplete outcome data (attrition bias)
Stool volume
Unclear risk Number of patients randomized was not
specified.
Selective reporting (reporting bias) Unclear risk Primary outcomes were not specified.
Other bias Low risk No sponsor.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cash 1973 Patients were not randomly assigned to treatment groups.
Chatterjee 1953 The article is not a controlled trial, and does not concern antimicrobial therapy
Gotuzzo 1994 An open, non-comparative trial.
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(Continued)
Greenough 1964 Patients were not randomly assigned to treatment groups.
Kobari 1967 Patients were not randomly assigned to treatment groups.
Kobari 1967a Patients were not randomly assigned to treatment groups.
Lahiri 1951 The antimicrobial treatment used is unknown and is not used in practice. The supportive care described was
inadequate
Mazumdar 1977 Previous work by the same author raises questions regarding the quality of randomizations and risk of bias
Mazumder 1974 Patients were poorly matched in baseline, which raises questions regarding the quality of randomizations and risk
for bias
Okuda 2007 The trial described was an in vitro experiment.
Pastore 1977 Patients were not randomly assigned to treatment groups.
Rabbani 1986 The publication is a review, not a trial.
Rabbani 1996 The publication is a review, not a trial.
Sagara 1994 Not all study arms contain cholera patients.
Seal 1954 Patients were not randomly assigned to treatment groups.
Seijo 1996 Patients were not randomly assigned to treatment groups.
Uylangco 1965 The antimicrobial treatment is no longer used in practice.
Uylangco 1966 Patients were not randomly assigned to treatment groups.
Uylangco 1967 Patients were not randomly assigned to treatment groups.
Uylangco 1978 Patients were not randomly assigned to treatment groups.
Uylangco 1984 Patients were not randomly assigned to treatment groups.
Wallace 1968 The publication is an editorial letter, not a trial.
Woodward 1969 Patients were not randomly assigned to treatment groups.
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Characteristics of studies awaiting assessment [ordered by study ID]
Chatchai 1994
Methods Unknown
Participants Unknown
Interventions Doxycycline 300 mg, single dose
Tetracyline 500 mg four times per day
Outcomes Unknown
Notes This reference came up in the search conducted in The Cochrane Library:
http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/179/CN-00617179/frame.html
There are no UK holdings for the journal. This publication was requested as a World Wide Search by Caroline
Hercod in December 2009; the search is still ongoing
Characteristics of ongoing studies [ordered by study ID]
Khan˙Ongoing
Trial name or title Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy ofMultiple-Dose Ciprofloxacin
With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Strains of V.
Cholerae O1 or O13
Methods Interventional trial
Allocation: randomized
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double blind (subject, investigator)
Primary purpose: treatment
Participants 18 to 60 year old males, duration of diarrhoea not exceeding 24 hours
Interventions Ciprofloxacin, twice per day for 3 days, dose not specified.
Azithromycin, 1 g Azithromycin single dose.
Outcomes Primary Outcome Measures:
• To determine whether clinical success of therapy in the two treatment regimens are comparable.
[ Time Frame: 48 hours ]
Secondary Outcome Measures:
• Compare the rates of bacteriological success.
• Compare the diarrhoea duration.
• Compare stool volume of patients.
• Measure stool concentrations of the two drugs and compare them with MICs of V. cholerae.
• Record and compare adverse events.
[ Time Frame: 48 hours ]
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Khan˙Ongoing (Continued)
Starting date July 2007
Contact information Wasif A Khan, MBBS, MS (880-2) 8860523-32 ext 2348, wakhan@icddrb.org
Notes Contact with Dr. Khan regarding this trial was established on February 2010, at which point he was in the
process of data handling and could not share information
Saha˙Ongoing
Trial name or title Randomized, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of
Ciprofloxacin Oral Suspension 20 Mg/Kg With a 3-Day Course of Erythromycin Oral Suspension Admin-
istered in a Dose of 12.5 Mg/Kg Every 6 Hours (12 Doses) in the Treatment of Children,With Clinically
Severe Cholera Due to V. cholerae O1 or O139.
Methods Interventional trial
Allocation: randomized
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Age: 2 to 15 years. Gender: male. Duration of illness: < 24 hours. Written informed consent for participation
in the study from either of the parents, or guardian, and oral assent from children aged 8 years
Interventions Ciprofloxacin Oral Suspension, 20 mg/kg, single dose.
Erythromycin Oral Suspension, 12.5 mg/kg four times per day, for 3 days
Outcomes Primary Outcome Measures:
• Rates of clinical success
Secondary Outcome Measures:
• Rates of bacteriologic success at test of cure visit.
• Duration of diarrhoea.
• Rates of clinical relapse.
• Rates of bacteriologic relapse.
• Duration of faecal excretion of V. cholerae O1 or V. cholerae O139.
• Measurements of six-hourly volume of watery stool will be done for the period in which patients are
hospitalized.
• Proportion of patients requiring unscheduled intravenous fluids.
• Frequency of vomiting and its volume.
• Frequency of stool per day.
• Frequency of vomit per day.
• Safety.
• PK-assessment of serum and stool.
Starting date May 2001
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Saha˙Ongoing (Continued)
Contact information Debasish Saha,MBBS,MS, International Centre for Diarrhoeal Disease Research, Bangladesh, dsaha@icddrb.
org
Notes An attempt to contact the author was made on February 2010.
Saha˙Ongoing˙B
Trial name or title Randomized, Double-Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin
Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to V.
cholerae O1 or O139
Methods Interventional trial
Allocation: randomized
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double blind
Primary Purpose: treatment
Participants 18 to 60 year old males, duration of diarrhoea not exceeding 24 hours
Interventions Azithromycin, single dose.
Ciprofloxacin, single dose.
Outcomes Primary Outcome Measures:
• Clinical success.
• Bacteriological success.
Secondary Outcome Measures:
• Rates of clinical and bacteriologic relapse.
• Duration of diarrhoea in hours, and duration of faecal excretion of V. cholerae O1 or O139 in days.
• Volume of watery/liquid stool for each 6 and 24 hour of the study, and also the total amount of
watery/liquid stools during the study period.
• Frequency of vomiting and the amount of vomitus, and proportion of patients with vomiting on each
study day.
• Intake of oral and intravenous fluids for each 24 hour as well as the entire duration of the study.
• Proportion of patients with resolution of diarrhoea on each study day.
• Proportion of patients with a positive culture for infecting V. cholerae O1 or O139 on each study day.
Starting date December 2002
Contact information Debasish Saha,MBBS,MS, International Centre for Diarrhoeal Disease Research, Bangladesh, dsaha@icddrb.
org
Notes An attempt to contact the author was made on February 2010.
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D A T A A N D A N A L Y S E S
Comparison 1. Antimicrobial versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 18 1479 Mean Difference (IV, Random, 95% CI) -36.77 [-43.51, -30.
03]
1.1 Norfloxacin 3 123 Mean Difference (IV, Random, 95% CI) -10.80 [-14.13, -7.
48]
1.2 Ciprofloxacin 1 48 Mean Difference (IV, Random, 95% CI) -43.37 [-57.48, -29.
27]
1.3 Tetracycline 11 665 Mean Difference (IV, Random, 95% CI) -47.38 [-52.36, -42.
41]
1.4 Doxycycline 3 91 Mean Difference (IV, Random, 95% CI) -25.44 [-38.90, -11.
99]
1.5 Erythromycin 2 46 Mean Difference (IV, Random, 95% CI) -33.73 [-56.53, -10.
92]
1.6 TMP-SMX 4 100 Mean Difference (IV, Random, 95% CI) -30.76 [-49.33, -12.
18]
1.7 Chloramphenicol 3 196 Mean Difference (IV, Random, 95% CI) -37.17 [-50.14, -24.
20]
1.8 Furazolidone 4 210 Mean Difference (IV, Random, 95% CI) -34.12 [-49.52, -18.
72]
2 Stool Volume 17 1536 Ratio of means (Random, 95% CI) 0.50 [0.45, 0.56]
2.1 Norfloxacin 2 98 Ratio of means (Random, 95% CI) 0.61 [0.51, 0.74]
2.2 Ciprofloxacin 1 48 Ratio of means (Random, 95% CI) 0.42 [0.22, 0.82]
2.3 Tetracycline 12 720 Ratio of means (Random, 95% CI) 0.44 [0.39, 0.50]
2.4 Doxycycline 3 91 Ratio of means (Random, 95% CI) 0.64 [0.51, 0.81]
2.5 Erythromycin 2 84 Ratio of means (Random, 95% CI) 0.81 [0.48, 1.35]
2.6 TMP-SMX 1 26 Ratio of means (Random, 95% CI) 0.89 [0.46, 1.70]
2.7 Chloramphenicol 3 196 Ratio of means (Random, 95% CI) 0.54 [0.32, 0.90]
2.8 Furazolidone 4 210 Ratio of means (Random, 95% CI) 0.49 [0.33, 0.74]
2.9 Ampicillin 1 63 Ratio of means (Random, 95% CI) 0.57 [0.42, 0.79]
3 Deaths 6 299 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.05, 0.05]
3.1 Norfloxacin 2 98 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.07, 0.07]
3.2 Tetracycline 4 103 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.08, 0.08]
3.3 Doxycycline 2 65 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.11, 0.11]
3.4 Furazolidone 1 33 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.16, 0.16]
4 Clinical failure 10 1023 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.13, 0.34]
4.1 Fleroxacin 1 145 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.24, 0.62]
4.2 Tetracycline 6 431 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.05, 0.22]
4.3 Erythromycin 1 22 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.20, 1.10]
4.4 TMP-SMX 2 55 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.17, 0.66]
4.5 Chloramphenicol 2 185 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.05, 0.40]
4.6 Furazolidone 2 148 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.23, 1.54]
4.7 Sulfometoxine 1 37 Risk Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.40]
5 Hydration requirements 11 1201 Ratio of means (Random, 95% CI) 0.60 [0.53, 0.68]
5.1 Norfloxacin 2 98 Ratio of means (Random, 95% CI) 0.72 [0.60, 0.86]
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5.2 Tetracycline 8 604 Ratio of means (Random, 95% CI) 0.50 [0.43, 0.58]
5.3 Doxycycline 2 66 Ratio of means (Random, 95% CI) 0.76 [0.57, 1.02]
5.4 Erythromycin 2 84 Ratio of means (Random, 95% CI) 0.68 [0.38, 1.21]
5.5 TMP-SMX 1 26 Ratio of means (Random, 95% CI) 0.87 [0.35, 2.17]
5.6 Chloramphenicol 2 185 Ratio of means (Random, 95% CI) 0.55 [0.34, 0.87]
5.7 Furazolidone 2 75 Ratio of means (Random, 95% CI) 0.85 [0.60, 1.21]
5.8 Ampicillin 1 63 Ratio of means (Random, 95% CI) 0.44 [0.22, 0.88]
6 Pathogen excretion duration 11 1009 Mean Difference (IV, Random, 95% CI) -2.74 [-3.07, -2.40]
6.1 Tetracycline 10 616 Mean Difference (IV, Random, 95% CI) -3.05 [-3.43, -2.67]
6.2 TMP-SMX 1 29 Mean Difference (IV, Random, 95% CI) -3.20 [-4.93, -1.47]
6.3 Chloramphenicol 3 196 Mean Difference (IV, Random, 95% CI) -2.43 [-3.03, -1.82]
6.4 Furazolidone 3 168 Mean Difference (IV, Random, 95% CI) -2.04 [-2.71, -1.37]
7 Bacteriological failure 15 1147 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.16, 0.39]
7.1 Norfloxacin 3 142 Risk Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.11]
7.2 Fleroxacin 1 145 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.04, 0.32]
7.3 Ciprofloxacin 1 48 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.03, 0.26]
7.4 Tetracycline 7 320 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.13, 0.64]
7.5 Doxycycline 2 64 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.04, 0.30]
7.6 Erythromycin 3 108 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.09, 0.33]
7.7 TMP-SMX 4 94 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.13, 1.05]
7.8 Chloramphenicol 1 15 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.38, 1.41]
7.9 Furazolidone 2 148 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.25, 2.08]
7.10 Ampicillin 1 63 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.57, 0.99]
Comparison 2. Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 18 1479 Mean Difference (IV, Random, 95% CI) -36.77 [-43.51, -30.
03]
1.1 Low risk 4 203 Mean Difference (IV, Random, 95% CI) -25.41 [-40.82, -10.
01]
1.2 Unclear 9 638 Mean Difference (IV, Random, 95% CI) -34.26 [-40.32, -28.
20]
1.3 High risk 5 638 Mean Difference (IV, Random, 95% CI) -45.01 [-51.01, -39.
01]
2 Stool Volume 17 1536 Ratio of means (Random, 95% CI) 0.50 [0.45, 0.56]
2.1 Low risk 4 207 Ratio of means (Random, 95% CI) 0.68 [0.47, 0.99]
2.2 Unclear 8 700 Ratio of means (Random, 95% CI) 0.51 [0.46, 0.58]
2.3 High risk 6 629 Ratio of means (Random, 95% CI) 0.42 [0.36, 0.49]
3 Clinical failure 10 1023 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.13, 0.34]
3.1 Low risk 4 323 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.26, 0.63]
3.2 Unclear 3 196 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.09, 0.55]
3.3 High risk 3 504 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.04, 0.17]
4 Hydration requirements 11 1201 Ratio of means (Random, 95% CI) 0.60 [0.53, 0.68]
4.1 Low risk 4 203 Ratio of means (Random, 95% CI) 0.71 [0.57, 0.89]
4.2 Unclear 4 463 Ratio of means (Random, 95% CI) 0.59 [0.49, 0.71]
4.3 High risk 3 535 Ratio of means (Random, 95% CI) 0.50 [0.43, 0.58]
5 Pathogen excretion duration 11 1009 Mean Difference (IV, Random, 95% CI) -2.74 [-3.07, -2.40]
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5.1 Low risk 1 43 Mean Difference (IV, Random, 95% CI) -3.5 [-3.83, -3.17]
5.2 Unclear 5 359 Mean Difference (IV, Random, 95% CI) -2.26 [-2.69, -1.83]
5.3 High risk 5 607 Mean Difference (IV, Random, 95% CI) -3.07 [-3.43, -2.71]
6 Bacteriological failure 15 1147 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.16, 0.39]
6.1 Low risk 4 215 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.14, 0.88]
6.2 Unclear 10 912 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.13, 0.39]
6.3 High risk 1 20 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.72]
Comparison 3. Sensitivity analysis: Antimicrobial versus placebo/no treatment by time outcome definitions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration by outcome
definitions
18 1479 Mean Difference (IV, Random, 95% CI) -36.77 [-43.51, -30.
03]
1.1 Vague time definitions 9 441 Mean Difference (IV, Random, 95% CI) -28.51 [-36.65, -20.
38]
1.2 8 hours periods 9 1038 Mean Difference (IV, Random, 95% CI) -42.21 [-47.64, -36.
78]
2 Clinical failure at 48/72/96
hours
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 48 hours 2 198 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.20, 0.70]
2.2 72 hours 6 307 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.27, 0.51]
2.3 96 hours 4 608 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.04, 0.37]
3 Bacteriological failure 48/72/96
sub totals only
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 48 hours 10 747 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.19, 0.54]
3.2 72 hours 7 474 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.11, 0.37]
3.3 96 hours 4 313 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.14, 0.74]
Comparison 4. Antimicrobial versus placebo/no treatment subgrouped by severity of dehydration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 18 1479 Mean Difference (IV, Random, 95% CI) -36.77 [-43.51, -30.
03]
1.1 100% severe dehydration 6 296 Mean Difference (IV, Random, 95% CI) -26.24 [-35.66, -16.
82]
1.2 Others 12 1183 Mean Difference (IV, Random, 95% CI) -41.31 [-45.99, -36.
62]
2 Stool Volume 17 1575 Ratio of means (Random, 95% CI) 0.50 [0.45, 0.56]
2.1 100% severe dehydration 6 263 Ratio of means (Random, 95% CI) 0.58 [0.50, 0.66]
2.2 Others 11 1312 Ratio of means (Random, 95% CI) 0.48 [0.42, 0.56]
3 Clinical failure 10 1023 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.13, 0.34]
3.1 100% severe dehydration 2 73 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.04, 0.68]
3.2 Others 8 950 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.13, 0.37]
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4 Hydration requirements 11 1201 Ratio of means (Random, 95% CI) 0.60 [0.53, 0.68]
4.1 100% severe dehydration 3 186 Ratio of means (Random, 95% CI) 0.73 [0.65, 0.83]
4.2 Others 8 1015 Ratio of means (Random, 95% CI) 0.55 [0.47, 0.64]
Comparison 5. Antimicrobial vs. placebo/no treatment subgrouped by antimicrobial resistance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bacteriological failure arms with
no resistance only
9 611 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.06, 0.27]
1.1 Norfloxacin 3 142 Risk Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.11]
1.2 Fleroxacin 1 145 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.04, 0.32]
1.3 Ciprofloxacin 1 48 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.03, 0.26]
1.4 Tetracycline 3 185 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.09, 0.62]
1.5 Doxycycline 1 38 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.41]
1.6 Erythromycin 1 24 Risk Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.44]
1.7 TMP-SMX 1 29 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.27, 2.38]
Comparison 6. Azithromycin versus ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 2 375 Mean Difference (IV, Random, 95% CI) -32.43 [-62.90, -1.
95]
2 Stool Volume 1 195 Ratio of means (Random, 95% CI) 0.35 [0.28, 0.44]
3 Hydration requirements 2 362 Ratio of means (Random, 95% CI) 0.66 [0.52, 0.83]
4 Clinical failure 2 375 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.23, 0.44]
5 Bacteriological failure 2 375 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.16, 0.34]
Comparison 7. Azithromycin versus erythromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 2 179 Mean Difference (IV, Random, 95% CI) -12.05 [-22.02, -2.
08]
2 Stool Volume 2 172 Ratio of means (Random, 95% CI) 0.69 [0.56, 0.85]
3 Hydration requirements 2 179 Ratio of means (Random, 95% CI) 0.77 [0.56, 1.05]
4 Clinical failure 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 Bacteriological failure 2 179 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.80, 3.02]
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Comparison 8. Tetracycline versus doxycycline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 3 230 Mean Difference (IV, Random, 95% CI) -2.01 [-8.21, 4.19]
2 Stool Volume 3 230 Ratio of means (Random, 95% CI) 0.97 [0.83, 1.14]
3 Deaths 2 66 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.08, 0.08]
4 Hydration requirements 3 230 Ratio of means (Random, 95% CI) 0.91 [0.78, 1.06]
5 Pathogen excretion duration 2 66 Mean Difference (IV, Random, 95% CI) -0.46 [-1.03, 0.11]
6 Bacteriological failure 2 198 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.06, 0.68]
Comparison 9. Tetracycline versus quinolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 3 259 Mean Difference (IV, Random, 95% CI) -0.91 [-4.53, 2.72]
2 Stool Volume 2 234 Ratio of means (Random, 95% CI) 0.87 [0.75, 1.02]
3 Deaths 1 25 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.14, 0.14]
4 Clinical failure 1 202 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.33, 1.38]
5 Hydration requirements 2 234 Ratio of means (Random, 95% CI) 0.98 [0.90, 1.07]
6 Pathogen excretion duration 1 25 Mean Difference (IV, Random, 95% CI) 0.05 [-0.42, 0.52]
7 Bacteriological failure 2 234 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.14, 6.82]
Comparison 10. Tetracycline versus TMP-SMX
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 2 152 Mean Difference (IV, Random, 95% CI) -6.44 [-10.93, -1.96]
2 Clinical failure 2 152 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.34, 0.92]
3 Pathogen excretion duration 1 45 Mean Difference (IV, Random, 95% CI) -1.10 [-1.74, -0.46]
4 Bacteriological failure 3 173 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.71, 2.02]
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Comparison 11. Tetracycline versus chloramphenicol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 3 356 Mean Difference (IV, Random, 95% CI) -11.49 [-25.93, 2.
96]
2 Stool Volume 3 356 Ratio of means (Random, 95% CI) 0.72 [0.50, 1.04]
3 Clinical failure 2 340 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.13, 1.04]
4 Hydration requirements 2 340 Ratio of means (Random, 95% CI) 0.81 [0.53, 1.24]
5 Pathogen excretion duration 3 356 Mean Difference (IV, Random, 95% CI) -0.96 [-1.48, -0.44]
Comparison 12. Tetracycline versus furazolidone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 3 121 Mean Difference (IV, Random, 95% CI) -14.00 [-31.26, -0.
74]
2 Stool Volume 3 120 Ratio of means (Random, 95% CI) 0.63 [0.48, 0.83]
3 Deaths 2 73 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.07, 0.07]
4 Clinical failure 1 57 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.08, 0.79]
5 Hydration requirements 2 82 Ratio of means (Random, 95% CI) 0.63 [0.46, 0.87]
6 Pathogen excretion duration 2 64 Mean Difference (IV, Random, 95% CI) -0.89 [-1.98, 0.20]
7 Bacteriological failure 2 105 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.45, 1.08]
Comparison 13. Doxycycline versus quinolones
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 3 126 Mean Difference (IV, Random, 95% CI) 4.64 [-2.14, 11.42]
2 Stool Volume 4 435 Ratio of means (Random, 95% CI) 1.01 [0.82, 1.25]
3 Deaths 1 54 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.07, 0.07]
4 Hydration requirements 2 87 Ratio of means (Random, 95% CI) 1.18 [1.02, 1.35]
5 Bacteriological failure 4 386 Risk Ratio (M-H, Fixed, 95% CI) 5.84 [2.70, 12.65]
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Comparison 14. TMP-SMX versus erythromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 2 68 Mean Difference (IV, Random, 95% CI) 5.39 [-7.82, 18.60]
2 Clinical failure 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.14, 1.76]
3 Bacteriological failure 2 68 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.16, 0.12]
Comparison 15. Short versus long duration of treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diarrhoea duration 7 431 Mean Difference (IV, Random, 95% CI) 0.34 [-4.65, 5.32]
1.1 Long duration 24 hours 2 88 Mean Difference (IV, Random, 95% CI) -5.30 [-24.64, 14.
04]
1.2 Long duration 48 hours 2 204 Mean Difference (IV, Random, 95% CI) 1.01 [-2.26, 4.27]
1.3 Long duration 72 hours 2 85 Mean Difference (IV, Random, 95% CI) 3.63 [-16.16, 23.43]
1.4 Long duration 96 hours 1 54 Mean Difference (IV, Random, 95% CI) 6.60 [0.84, 12.36]
2 Stool Volume 8 486 Ratio of means (Random, 95% CI) 1.05 [0.94, 1.18]
2.1 Long duration 24 hours 2 88 Ratio of means (Random, 95% CI) 0.98 [0.72, 1.33]
2.2 Long duration 48 hours 2 204 Ratio of means (Random, 95% CI) 0.99 [0.83, 1.17]
2.3 Long duration 72 hours 2 85 Ratio of means (Random, 95% CI) 1.03 [0.76, 1.39]
2.4 Long duration 96 hours 2 109 Ratio of means (Random, 95% CI) 1.15 [0.82, 1.61]
3 Hydration requirements 6 403 Ratio of means (Random, 95% CI) 1.10 [0.99, 1.22]
3.1 Long duration 24 hours 1 48 Ratio of means (Random, 95% CI) 1.01 [0.66, 1.55]
3.2 Long duration 48 hours 2 204 Ratio of means (Random, 95% CI) 1.08 [0.91, 1.28]
3.3 Long duration 72 hours 1 32 Ratio of means (Random, 95% CI) 0.86 [0.27, 2.76]
3.4 Long duration 96 hours 2 119 Ratio of means (Random, 95% CI) 1.07 [0.83, 1.38]
4 Pathogen excretion duration 3 141 Mean Difference (IV, Random, 95% CI) 0.40 [0.11, 0.69]
4.1 Long duration 24 hours 1 48 Mean Difference (IV, Random, 95% CI) 0.90 [-0.21, 2.01]
4.2 Long duration 48 hours 1 40 Mean Difference (IV, Random, 95% CI) 0.25 [0.03, 0.47]
4.3 Long duration 72 hours 1 53 Mean Difference (IV, Random, 95% CI) 0.59 [0.16, 1.01]
5 Clinical failure 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Long duration 72 hours 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Long duration 96 hours 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Bacteriological failure 9 672 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.01, 2.32]
6.1 Long duration 24 hours 1 48 Risk Ratio (M-H, Fixed, 95% CI) 7.58 [0.41, 139.32]
6.2 Long duration 48 hours 2 286 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.87, 3.45]
6.3 Long duration 72 hours 3 125 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.58, 2.17]
6.4 Long duration 96 hours 3 213 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.61, 3.90]
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A D D I T I O N A L T A B L E S
Table 1. Detailed search strategies
Search set CIDG SR CENTRAL PUbMeda EMBASEa LILACS AIM SCI
1 Cholera Cholera
“Cholera”[MeSH]
Cholera Cholera$ Cholera Cholera
2 Cholerae Cholerae Cholera Cholerae random$ Cholerae Cholerae
3 1 or 2 1 or 2 Cholerae 1 or 2 aleator$ 1 or 2 1 or 2
1 or 2 or 3 1 and (2 or 3)
a Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011).
Table 2. Trial location abbreviations
Abbreviation Country
BGD Bangaladesh
CIV Cote d’Ivoire
IND India
IRN Iran
LKA Sri Lanka
NGA Nigeria
PAK Pakistan
PER Peru
SOM Somalia
THA Thailand
TUR Turkey
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Table 3. Optimal Information Size Calculations: Continuous outcomes
Outcome Hypothesis Power α error Mean in control
group
Mean in inter-
vention group
Standard devia-
tion
Total sample size
required
Diarrhoea
duration
Superiority 80% 5% 301 15 10 14
301 22 10 50
1301 65 40 12
1301 98 40 50
Duration of
pathogen ex-
cretion
Superiority 80% 5% 32 1.5 1 20
32 2.25 1 76
62 3 2 20
62 4.5 2 76
Calculations performed with http://www.sealedenvelope.com.
1 The mean duration of diarrhoea in the control groups ranged from 29.3 to 127.2 hours (Analysis 1.1).
2 The mean hydration requirements in the control groups ranged from 2.97 to 6 days (Analysis 1.6).
Table 4. Optimal Information Size Calculations: Dichotomous outcomes
Outcome Hypothesis Power α error Proportion in control
group
Proportion
intervention group
Total sample size re-
quired
Clinical failure Superiority 80% 5% 60%1 30%3 80
60% 45%4 342
12%2 6%3 708
12% 9%4 3272
Bacteriological
failure
Superiority 80% 5% 75% 37.5%3 48
75% 56.25%4 194
20% 10%3 394
20% 15%4 1806
Calculations performed with http://www.sealedenvelope.com.
1 The overall proportion of clinical failures in people randomized to placebo or no treatment was 61% (Analysis 1.4).
2 The overall proportion of clinical failures in people randomized to antibiotics was approximately was 12% (Analysis 1.4).
3 Based on a RR of 0.5.
4 Based on a RR of 0.75.
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5 The overall proportion of bacteriological failures in people randomized to placebo or no treatment was 74% (Analysis 1.7).
6 The overall proportion of bacteriological failures in people randomized to antibiotics was approximately was 20% (Analysis 1.7).
Table 5. Dose comparison
Study Antimicrobial Low dose High dose Duration Population
Pierce 1968 IND furazolidone 200 mg 400 mg 72 hours Adults
Alam 1990 BGD doxycycline 200 mg 300 mg Single dose Adults
De 1976 IND doxycycline Adults: 200mg;Chil-
dren: 4 mg/kg
Adults: 300mg;Chil-
dren: 6 mg/kg
Single dose Adults and children
Karchmer 1970
PAK
tetracycline 10 mg/kg/day in 4
doses
31-62mg/kg/day in 4
doses
7 days Children
Islam 1987 BGD tetracycline 1 g 2 g Single dose Adults
C O N T R I B U T I O N S O F A U T H O R S
YLK conducted the preliminary search. YLK and MP selected the studies for the review and extracted the data. AN and RB assisted in
risk of bias assessment and the second revision. MAS was consulted where problems arose. YLK performed all necessary calculations
for conversion of data and entered data into Review Manager 5. YLK and MP performed the data analysis. YLK and MP wrote the
first draft of the review and all authors revised and wrote the final review.
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External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Methods of pooling outcomes dependent on weight were changed from standardized mean differences (SMDs) to ratio of
means. SMDs had no clinical meaning and could not be translated into a clinically meaningful outcome because of the varying
standard deviations reported in the trials. The SMD analysis also abolished the heterogeneity that was apparent when looking at the
results of the individual trials.
• We decided to exclude antimicrobials that are not currently in clinical use for treating cholera.
• With regards to data analysis, in order to include all patients in trials with multiple study arms, we acted as suggested in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). For dichotomous results, we divided the number of events
and participants in the placebo arm, and for continuous results we divided the number of participants and used mean and standard
deviation as is. This was done instead of using the antimicrobial ’hierarchy’ first designed in the protocol for this review, which
allowed the inclusion of only one study arm versus, placebo from these trials.
• We added subgroup analyses based on timing definitions for monitoring and severity of dehydration at baseline. We omitted
sensitivity analyses regarding intention to treat in the outcome of clinical failure.
• We changed the time definitions for the outcomes of clinical failure and bacteriological failure.
• We did not include the outcomes of clinical and bacteriological relapse in our review. The reason for this decision was that
relapse could occur only in patients that had been cured (for example, patients who never stopped purging could never relapse). This
definition caused a bias against the arms receiving antimicrobial treatment, which seemed to experience relapse more than the
placebo/no treatment arms.
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